

PROGRAMME



**The leading European partnering event for
early-stage deals and investment rounds
in the Life Sciences field**

**December
12th & 13th, 2023**

MARSEILLE

**December
15th, 2023**

ONLINE MEETINGS

12TH EDITION

Nurturing our world and humankind by advancing care for animals

zoetis.com

zoetis

WELCOME *note*

Welcome to BioFIT 2023, in Marseille! It is our great pleasure to extend a warm welcome to you all to the 12th edition of BioFIT, Europe's leading partnering event for academia-industry collaborations, early-stage deals and investment rounds in the Life Sciences sector.

BioFIT serves as a unique platform for fostering collaboration and innovation within the Life Sciences industry and we are thrilled to see so many leaders, experts, and innovators coming together to exchange ideas and explore potential partnerships.

Over the next two days, we encourage you to take full advantage of the networking opportunities, insightful sessions, and interactive discussions that BioFIT has to offer. Let's work together to drive the future of bio-innovation and create meaningful connections that will shape the industry for years to come.

We thank our steering committee, sponsors, exhibitors, speakers, supporters and institutional partners without whom this event could not be organised.

So, once again, welcome to BioFIT 2023, let's make this edition a resounding success together!



Étienne Vervaecke
General Manager
Eurasanté & Clubster NHL



Émilie Royère
General Manager
Eurobiomed



Caroline Dreyer
General Manager
BioValley France

ORGANISERS



INSTITUTIONAL PARTNERS



BIOFIT AT A GLANCE

With the highest participation rate of academics, TTOs and research institutions, BioFIT is the ideal starting point for academia-industry collaborations.

BioFIT has taken on a whole new dimension by becoming the main place in Europe for technology transfer and sourcing of early-stage innovations from public research institutions, academic spin-offs and emerging biotech companies. Together with big pharma, biotech and diagnostics companies, BioFIT serves as a platform for building partnerships for all stakeholders from academia and industry.

BioFIT is also the European marketplace for pre-seed, seed and Series A investments in Life Sciences.

1,000
delegates

35
countries
represented

65
high-level
speakers

100
exhibitors

57
innovative
presentations

TABLE OF CONTENTS

- 9 Organisers
- 11 Steering Committee
- 12 Sponsors

24 PROGRAMME AT A GLANCE

28 NETWORKING

- 28 One-on-one meetings
- 29 Who will you meet?
- 30 Project - CEO matchmaking

32 PITCH SESSIONS

- 32 Jury members
- 33 Start-up Slams
- 37 Collaborative and Licensing Opportunity Presentations
- 39 Animal Health Presentations

40 CONFERENCES

- 41 Plenary session
- 42 Track 1: Best practices in R&D collaborations
- 44 Track 2: Nurturing and licensing early-stage assets
- 46 Track 3: From pre-seed to Series A: Accessing early-stage investment
- 48 Track 4: Animal Health highlights

50 HOSTED EVENTS

- 50 R&D dating for Animal Health and Innovation
- 51 LEAP-BIO AI-powered digital platform: novel IP Licensing intermediary services of early-stage assets in pharma and biotech's

52 EXHIBITION

- 52 Exhibitor list & floor plan
- 54 Exhibitor descriptions
- 72 They support us

Marseille: Where innovation and collaboration thrive

Located in the heart of the Sud-Provence-Alpes Côte d'Azur region, Marseille is a dynamic hub for the biotech industry.

Renowned for its Mediterranean charm and world-class research environment, the city offers a dynamic ecosystem that attracts top scientific minds and innovative biotech companies. With a rich history of discovery and a spirit of collaboration, Marseille has become a leading research centre, fostering interdisciplinary collaborations and accelerating advances in Life Sciences.

The region's strategic location, combined with its state-of-the-art facilities and a range of industry-focused initiatives, makes Marseille a destination of choice for biotech pioneers looking to drive innovation, nurture start-ups and forge valuable partnerships at the forefront of scientific progress.





With 92 municipalities and 1.8 million inhabitants, the Aix-Marseille-Provence metropolis is the economic capital of the South region, the Euro-Mediterranean center of exchanges and the 2nd French metropolis in demographic terms. With 92,000 jobs, 20,000 students, 47 research laboratories, a world competitiveness cluster, 600 innovative companies and four axes of excellence (microbiology, infectious diseases and genetic diseases; neurosciences; medical instrumentation and immunology) the health sector supported by the Metropole is positioned as an international sector.



ORGANISERS



lille.eurasante.com

Eurasanté is a technology transfer tool, an incubator, an accelerator and a cluster manager in the Health field in Northern France. Eurasanté assists French and foreign companies, entrepreneurs, scientists and clinicians with their innovation and development projects. The region includes over 1,000 healthcare companies with 32,000 employees in this sector. Eurasanté also promotes and develops the Eurasanté bio-business Park which hosts 7 hospitals, 4 universities, 7 specialised schools, 170 companies and 50 laboratories within an European-wide scientific and medical site. Eurasanté also organises four international healthcare-related partnering events that aim to increase and improve interaction between academia and industry: BioFIT (Life Sciences), MedFIT (MedTech, Diagnostic), MEDigIT (Digital Health), NutrEvent (Food, Feed, Nutrition, Health) and AgeingFit (Healthy Ageing).



www.clubster-nhl.com

Clubster NHL is a competitiveness cluster and a network gathering 360 members committed to innovation in health and nutrition. Clubster NHL aims to connect academia, industry and health professionals, and to foster innovation for better health and sustainable food. Its goal is to bring together and support stakeholders from the health and food sectors in designing, developing and financing their future products and processes.



www.biovalley-france.com

Based in Eastern France, the BioValley France cluster brings to the health sector its unique expertise and personalized support around 4 fields of expertise: Drugs and Innovative Therapies, E-health, Medical Technologies and Diagnosis. For more than eighteen years, BioValley France has built a powerful community in order to deploy a strong network mixing academics and industrials in the health sector: more than 203 members et 55 partners have decided to join the Cluster in order to share, exchange and develop tomorrow's innovation in the best conditions. BioValley France offers services in: Business Competitiveness, Innovative Project, International Relations, Visibility and Influence.



www.eurobiomed.com

Founded in 2009 by regional stakeholders, Eurobiomed is the Life Science cluster from Southern France. We gather more than 420 innovative biotech and medtech companies, as well as leading research institutes, hospitals and universities. We lead territorial initiatives and help our members businesses and research organisations to innovate, finance, develop and achieve their scientific and business objectives, to ultimately improve the treatment and the lives of patients.

Eurobiomed tops European rankings in all stages of innovation: education, basic, translational and clinical research, technological innovation centers, start-ups and industrial success stories. Some of Eurobiomed main assets are the number of people involved, but also the quality of the network and trust that is established between its members, which reinforces the interactions and facilitates collaborations.



SCIENCE WILL MAKE THE BREAKTHROUGH.

We believe science can cure every human disease.

STEERING COMMITTEE

PHARMA, BIOTECH



Damien Chopy
Senior Director, Business Development
Roche Pharma Partnering



Guy Hélin
Co-founder & CEO
Syngulon



Marie-Ange N'Zoutani
Head of Acceleration Office
Sanofi



Eva Dahlén
Director, Search & Evaluation
Novo Nordisk



Sebastian Karrer
Head of Business Development and
Licensing Region Europe & EMEA
Bayer



Niharika Sharma
Principal, Corporate Development
Roivant Sciences



Florence Dal Degan
Senior Director, External Innovation,
Rare Diseases and Neuroscience
Ipsen



Chloé Leprêtre
Head of Search & Evaluation
Servier



Philippe Verwaerde
CEO & Chief Scientific Officer
Alzproctect



Julie Edwards
Director, Alliance Management
Boehringer Ingelheim



Alain Martelli
Emerging Science Lead, France
Pfizer



Joachim Vogt
Director, Search and Evaluation,
International
AbbVie

ACADEMIA, TTOS



Hervé Ansanay
BIOTECH Alliance Manager,
Strategic Alliance Team
Réseau SATT



Garold Breit
CEO
Breit Ideas LLP



Esther Lange
Industry Liaison Manager
Ascenion



Jürgen Bauer
Deputy Managing Director
EMBLEM Technology Transfer



Jean-Luc Chagnaud
Head of Business Development in
Health Innovations
Aquitaine Science Transfert

INVESTORS



Clément Bertholet
Partner
AdBio Partners



Juliette Lee
Associate
EGT Life Sciences Dementia Fund



Daniel Parera
Senior Advisor
Kurma Partners
& Co-Founder, CEO & CMO
IcanoMAB



Frank Hensel
Principal
High-Tech Gründerfonds



Jérôme Majoie
General Manager
Foumier-Majoie Foundation



Zhizhong Yao
Principal, Biotech & Biopharma
Sofinnova Partners

ASSOCIATIONS, CLUSTERS



Caroline Dreyer
General Manager
BioValley France



Jean-Louis Hunault
President
SIMV - The French association of the
animal health industry



Corinne Szilagyi
Senior Partner
Biotech Développement Conseils
& Member of the Business Development
Committee
France Biotech



Yohan Grosjean
Communication Officer
AFSSI - The French association of
outsourcing and innovative companies



Émilie Royère
General Manager
Eurobiomed



Etienne Vervaecke
General Manager
Eurasanté & Clubster NHL

OUR SPONSORS

PLATINUM SPONSORS



We deliver the industry's most comprehensive portfolio of high-quality products, services and testing for biopharmaceutical manufacturing.

We are proud to provide drug manufacturers with process development expertise and technologies, such as continuous bioprocessing.

We collaborate with the world's leading drug developers to help bring drug therapies to patients. We bring our pharmaceutical and biotechnology expertise and products to improve every step of the manufacturing process, while providing startups with holistic support to build and scale up theirs.

www.merckgroup.com

Merck's presentation: From DNA to industrialization - supporting Emerging Biotech along the drug journey - Wednesday, December 13th | 2.00 - 2.15 pm | Innov'Area



As the world's leading animal health company, we are driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After 70 years innovating ways to predict, prevent, detect, and treat animal illness, we continue to stand by those raising and caring for animals worldwide – from livestock farmers to veterinarians and pet owners. A Fortune 500 company, we generated revenue of \$8.1 billion in 2022 with ~13,800 employees.

www.zoetis.com - **STAND C8**

Zoetis' presentation: Innovation and One Health: How can partnerships accelerate strategic innovation? - Tuesday, December 12th | 3.15 - 3.45 pm | Marseilleveyre room

OUR SPONSORS

GOLD SPONSOR



At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us.

www.pfizer.com

Pfizer's presentation: Partnering with Pfizer Research and Development
Wednesday, December 13th | 11.45 am - 12.15 pm | Marseilleveyre room

OUR SPONSORS

SILVER SPONSORS



As an independent company active in both human and animal health, Boehringer Ingelheim has learned over generations that the challenging path towards health innovation requires long-term commitment, resilience, and transformative action. Decades of cutting-edge science and innovation has enabled us to deliver many pioneering breakthroughs in some of the most devastating diseases and challenging areas we face globally. Continuing this journey hinges on collaboration.

We believe that working together with our global community of partners brings critical diversity to innovation and accelerates the next breakthroughs in human and animal health that will transform lives now and in generations to come. This collective power, in the tireless pursuit of science and solutions, enables us to build together a healthier, more sustainable, and equitable tomorrow.

www.boehringer-ingelheim.com



GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases characterized by high unmet medical needs. GENFIT is a pioneer in liver disease research and development with a rich history and strong scientific heritage spanning more than two decades. Today, GENFIT has a growing and diversified pipeline with programs at various development stages. The Company's area of focus is Acute on Chronic Liver Failure (ACLF). Its ACLF franchise consists of five assets in development. Other assets target other life-threatening disease indications such as cholangiocarcinoma (CCA) and Urea Cycle Disorders (UCD)/Organic Acidemias (OA).

www.genfit.com



Working with the life-science community to be *first4patients*

Inspired by patients, driven by science and powered by our growing global community of partners, we're working hard to discover and develop the next generation of transformative medicines that will change patients' lives.

Working together in:

Cardio-Renal-Metabolic Diseases | Immunology & Respiratory Diseases | Mental Health Disorders
Oncology | Retinal Health | Research Beyond Borders | Technologies



Find out more

Life forward



The ACLF Company

Developing a pipeline of therapies to **reshape** the current treatment landscape for patients with **Acute-on-Chronic Liver Failure (ACLF)** and other rare life-threatening liver diseases with **high unmet medical needs**

OUR SPONSORS

SILVER SPONSORS



Spartners by Servier & BioLabs is on a mission to empower life science innovation in Paris-Saclay by creating a unique place for life science startups to test, develop and grow game changing ideas. Spartners offers state-of-the-art facilities with fully equipped laboratory and office spaces that are supported by an experienced, dedicated, technical team. Designed to build community, Spartners enables high-potential life science companies to work, collaborate and innovate in a setting perfectly suited to meet their needs. Our exclusive approach combines BioLabs' expertise with Servier's know-how, making it stand out in France.

www.servier.com/en/newsroom/spartners-biotech-start-up-welcome-to-apply - STAND C19



Founded in 2012, X'PROCHEM is a CRO (Contract Research Organization) specialized in chemical protein synthesis.

We design and produce therapeutic proteins for our pharmaceutical and biotech partners. We manufacture complex and highly customized proteins up to 400 amino acids (40 kDa) by using an automated process.

www.xprochem.com - STAND B3-A4

Our Services


- 2 000 sqm of premium life science facility
 - Coworking lab
 - Private Lab & private Office
 - Coworking offices
 - Meeting room
 - Gathering space
- State-of-the-art laboratory equipment with a dedicated technical team
- Benefits from the advantages of Biolabs network

Spartners by Servier & BioLabs was designed alongside our founding partner Servier, to be the best coworking space in Paris-Saclay for life sciences startups - a unique place to test, develop and grow revolutionary ideas.

Our mission is to support startups in their research and development phase, accelerating their "time to market."

Spartners
by Servier & BioLabs
a unique Bio innovation hub

PURE & SAFE THERAPEUTIC PROTEINS !



- «Protein on demand» Service
- Chemical synthesis of proteins
- Endotoxin-free (very high purity)
- Maximized bioactivity

03.28.55.51.30

contact@xprochem.com

154 rue du Dr.Yersin, 59120 Loos

www.xprochem.com



OUR SPONSORS

BRONZE SPONSORS



Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2022, the Group employed around 101,000 people and had sales of 50.7 billion euros. R&D expenses before special items amounted to 6.2 billion euros.

www.bayer.com



Ipsen is a public global, mid-sized biopharmaceutical company focused on transformative medicines in Oncology, Rare Disease and Neuroscience. With Specialty Care sales of over € 3 bn in FY 2022, Ipsen sells medicines in over 100 countries. Ipsen has 5,200 employees worldwide and innovative research located in leading biotechnological and life-science hubs in France, UK, Sweden, US and China. For more information, visit ipsen.com and get in touch with our partnering team!

www.ipsen.com



FOR MANY AN ACTIVE LIFE | OUR SCIENTISTS
STOPS FAR TOO EARLY | WON'T ACCEPT THAT




By 2050 the world's population over 60 will have doubled to two billion, making age-related illness an even greater challenge for society. That's why we're seeking to help people stay healthier and more active in later life, be it through more targeted treatments

for cancer and cardiovascular conditions, solutions for eye diseases, or ways to keep those with arthritis moving. Because life shouldn't stop at 60 — not by any means. To find out how our innovations are helping to change lives for the better, visit our website : www.bayer.fr.

Science for a **better life**

RUNNING OUT OF BATTERY?

You can borrow a powerbank at the Partnering Desk!



OUR SPONSORS

BRONZE SPONSORS



MSD has a strong history of success in translating cutting-edge research into life-saving medical breakthroughs. Our scientific advances have made a difference in the lives of millions of patients worldwide... and many of these advances were the result of partnerships. In 2016, more than 60% of our human health sales were attributable to alliance partnerships and patents and we continue to work with our partners in some of the most challenging areas of biomedical research. With more than 100 business development transactions since 2015, our team has experience working on collaborations from discovery to clinical-stage programs regardless of therapeutic area or modality. We believe that by working together we can play a major role in transforming global health care. Together we can invent for life.

www.msd.com



Roche is the world's largest biotech company and #1 investor into R&D, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the CNS. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare. Our Pharma Partnering team provides comprehensive BD and alliance management support for Roche and Genentech's R&D units and the broader pharmaceutical division. Alongside the broad internal pipeline, external innovation has always been a critical component of our R&D strategy.

www.roche.com

Using the power of leading-edge science to save and improve lives around the world

For more than a century, we've been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for some of the world's most challenging diseases.

At MSD, we rise to the challenge in pursuit of better health outcomes.



Copyright © 2022 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. HQ-NON-009917/22



We value your ideas as much as our own

Find out more on roche.com/partnering

OUR SPONSORS

CONTRIBUTING SPONSORS



Launched in 2021, Captech Santé, is an early-stage fund, investing in projects in Biotech, Medtech, Digital Health and Nutrition. With a capital of €35 to €40 million, the fund invests in Seed or Series A. Thanks to its expertise and integration in the healthcare ecosystem, Captech supports its investments over the long term, and co-invests with international funds.

www.finorpa.fr/gestion/metiers/captech-sante-nutrition



Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases such as diabetes, obesity and cardiovascular disease as well as rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease.

www.novonordisk.com



PROGRAMME AT A GLANCE

12

DECEMBER



	Lille room	Marseilleveyre room	Innov'Area	Partnering booths
8.30 am 9.00 am	Welcome coffee			One-on-one meetings
9.00 am 10.30 am	Adding value to early-stage assets through partnering: What are the working models and how to valorise the partnerships?	LEAP-BIO AI-powered digital platform session Collaborative and Licensing Opportunity Presentations Infectious diseases	Start-up Slams Oncology Drug discovery	
10.30 am 11.00 am	Networking break			
11.00 am 12.30 pm	<div>Lille room</div> <div>PLENARY SESSION</div> <div>Biopharma industry has been facing uncertainties in 2023: What is the impact for early-stage partnering strategies?</div>			One-on-one meetings
12.30 pm 2.00 pm	Lunch			
2.00 pm 3.00 pm	Exploring the pharma-VC relationship: How do they build complementary investment strategies?	Sourcing innovations from a more mature human health market to build assets and start-ups in animal health	Start-up Slams Inflammation	
3.15 pm 4.30 pm	How are tech transfer offices selecting the projects to back?	Innovation and One Health: How can partnerships accelerate strategic innovation? <i>zoetis</i>	Start-up Slams CNS	
4.30 pm 5.00 pm	Networking break			
5.00 pm 6.15 pm	Exploring collaborative practices between biotech start-ups and academia	Collaborative and Licensing Opportunity Presentations Cell & gene therapy CNS	Animal Health Presentations	
From 6.00 pm	Cocktail <div>AFSSI Pavilion - Stand E7-D10</div>			
From 6.45 pm				

- ◆ **TRACK 1** BEST PRACTICES IN R&D COLLABORATIONS
- ◆ **TRACK 2** NURTURING AND LICENSING EARLY-STAGE ASSETS
- ◆ **TRACK 3** FROM PRE-SEED TO SERIES A: ACCESSING EARLY-STAGE INVESTMENT

- ◆ **TRACK 4** ANIMAL HEALTH HIGHLIGHTS
- ◆ **PROJECT - CEO MATCHMAKING**

13

DECEMBER

	Lille room	Marseilleveyre room	Innov'Area	Partnering booths
8.30 am 9.00 am	Welcome coffee			One-on-one meetings
9.00 am 10.00 am	What's new in non-dilutive funding across Europe and how to prepare for it?	Collaborative and Licensing Opportunity Presentations Oncology	Start-up Slams Drug discovery Diagnostic	
10.00 am 10.30 am	Networking break			
10.30 am 11.30 am	What are pharma companies' expectations for pre-competitive research?	Biotech start-up governance: What makes a good foundation for a company to deliver and grow?	Start-up Slams Cardiovascular & Metabolic diseases Technology platforms Drug delivery	
11.45 am 12.30 pm	From Seed to Series A: What will spark investors' interest in 2024?	Partnering with Pfizer Research and Development 		
12.30 pm 2.00 pm	Lunch	VIP lunch area Investor lunch		
2.00 pm 3.15 pm	From lab to start-up: Let's hear about successful spin-out journeys		 From DNA to industrialization Start-up Slams Immunology Onco-immunology	
3.15 pm 3.30 pm	Networking break			
3.30 pm 4.30 pm	Best practices in managing early-stage academia-industry collaborations			
4.30 pm	Innov'Area Pitch sessions - Award Ceremony			

15

DECEMBER

Online meetings

📶 CONNECTING TO THE WIFI 📶

1

Choose **FREE WIFI CHANOT** network

2

A page opens: check the box and validate

Welcome to Provence-Alpes Côte d'Azur!

HERE, Innovative therapies are a sector of excellence, attracting talent and investment.

Are you a market leader
or tomorrow's
champion?

We offer you tailored
support to make your
project a success.

Come and visit us on stand n°C7-A8/12



Find out more:
www.maregionsud.fr
www.risingsud.fr

Bio Party



DECEMBER 12th • FROM 6.45 PM
Parc Chanot • Reception Hall

NETWORKING | COCKTAILS
ENTERTAINMENT | DANCING



Biofit

FOSTERING
INNOVATION
& TRANSFER

ONE-ON-ONE MEETINGS



TO MEET YOUR FUTURE PROJECT PARTNERS, OBTAIN FUNDING AND ACCELERATE INNOVATION

BioFIT's partnering platform allows to pre-organise 30-minute one-on-one meetings and optimise the time spent at the event.

BioFIT's partnering platform is powered by: inpart

It's time to meet your future partners:

- Print out your meeting schedule at the Partnering Desk or consult it via your partnering account on inova-event.com/BioFIT2023 or on the « One-on-One Partnering » app.
- Attend your one-on-one meetings at the time and place indicated.
- Remember to check your schedule regularly throughout the event.

Download the « One-on-One Partnering » app to receive your agenda updates

Organise your agenda | Request and manage meetings | Mobile messaging



You did not get the chance to schedule all your meetings?
BioFIT continues online on December 15th

WHO WILL YOU MEET?



25% TTOs, Research institutions, Incubators, Academics



25% Biotech companies



20% Pharma & Diagnostic companies



10% R&D services - Preclinical CROs and CDMOs



10% Investors (pre-seed, seed and Series A)



5% Consulting companies, law firms



5% Associations, clusters, media



INVESTOR LUNCH

BioFIT has the pleasure to organise an **Investor Lunch** on **Wednesday, December 13th** at 12.30 pm within the VIP lunch area.

This dedicated lunch will offer the opportunity to investors to **discuss early-stage investment trends** and exchange on the **2023 highlights**. More importantly, this networking time will be the perfect moment to solidify coinvestment networks.

Investors can sign-up on-site at the partnering desk before December 13th.

PROJECT – CEO MATCHMAKING

**You are a bioentrepreneur seeking new challenges
or you are looking for a passionate CEO to lead your project?**

The Project - CEO matchmaking is made for you!

As talented CEOs are frequently sought-after by many players in the biotech industry, the Project – CEO matchmaking activity aims to connect representatives of emerging start-ups, technology transfer offices, incubators, and investing networks with CEOs and aspiring CEOs.

Find the perfect match:

- Any incubator, technology transfer entity or scientific founder looking for an entrepreneur to lead their innovative projects is welcome to participate in the matchmaking activity to **meet with qualified candidates!**
- If you are a bioentrepreneur looking for a new project to undertake: projects looking for a CEO are visible on the platform and easily identifiable.



Get inspired:

Having the right team is essential for the development of a biotech project. The Project – CEO matchmaking activity also offers a **conference session** to get inspired and explore the best ways to find the right talents for a successful project:

Day 2 - Wednesday, December 13th | 10.30 - 11.30 am Marseilleveyre room

Biotech start-up governance:

What makes a good foundation for a company to deliver and grow?

One of the most important indicators of a start-up's later success is the quality of the founding team and its CEO. What does it mean to be a founder? When the time comes of building a team around the founder(s), how to identify the right people and is the founder always the best option to run the company? What is the ideal composition for the board, the scientific committee, and the executive committee? What are the most prevalent governance problems start-ups face while scaling and how to address them? How to keep the initial team motivated and invested when the company is growing? How to bring the right investors on board?



Claudia Andretta

Founder, Strategic Science &
Business Advisor
Sichem Bio



Farzad Abdi-Dezfuli

Partner
Sarsia



Stephanie Munk

Senior Associate
Sunstone Life Science Ventures



Bart Wuurman

CEO
Apaxen



Agostino Romeo

Senior Technology Transfer and
Business Development Manager
Institute for Bioengineering
of Catalonia

PITCH SESSIONS

The BioFIT pitch sessions offer the opportunity to detect the most innovative and promising start-ups, R&D projects and licensing opportunities in order to foster partnerships and business development in the Life Sciences and Animal Health fields.

The most innovative start-up, most promising technology and most innovative animal health project will be announced during the **Award Ceremony** on:



December 13th at 4.30 pm within the **Innov'Area**

JURY MEMBERS

Farzad Abdi-Dezfuli, Partner, **Sarsia** 🇫🇷
Jürgen Bauer, Deputy Managing Director, **EMBLEM Technology Transfer** 🇩🇪
Maurizio Bettiga, Chief Innovation Officer, **Italbiotec** 🇮🇹
Damien Choppy, Senior Director, Business Development, **Roche Pharma Partnering** 🇫🇷
Adrien Clavairolly, Senior Associate, **AdBio Partners** 🇫🇷
Caroline Coisne, Technology Transfer Officer, **Eurasanté** 🇫🇷
Florence Dal Degan, Senior Director, External Innovation Rare Diseases & Neuroscience, **IPSEN** 🇫🇷
Ankita Das, Biotech Venture Developer, **NLC Health** 🇮🇹
Francesca Freddi, Innovation Manager, **Italbiotec** 🇮🇹
Frank Hensel, Principal, **High-Tech Gründerfonds** 🇩🇪
Jan-Philipp Kruse, Senior Director BD&L & Open Innovation – Head of Co.Lab Berlin Incubator, **Bayer** 🇩🇪
Esther Lange, Industry Liaison Manager, **Ascenion** 🇩🇪
Chloé Leprêtre, Head of Global R&D Search and Evaluation, **Servier** 🇫🇷
Jerome Majoie, General Manager, **Fournier-Majoie Foundation** 🇫🇷
Tugrul Ozdemir, Associate, Seed Investments, **Novo Holdings** 🇩🇪
Eleanor Price, Investment analyst, **Thuja Capital** 🇬🇧
Iraida Soria-Espinosa, Senior Innovation and Business Manager, **UK Dementia Research Institute** 🇬🇧
Corinne Szilagyi, Senior Partner, **Biotech Développement Conseils**, Member of the Business Development Committee, **France Biotech** 🇫🇷
Joachim Vogt, Director, Search and Evaluation International, **Abbvie** 🇩🇪
Jean-Louis Hunault, President, **SIMV - The French association of the animal health industry** 🇫🇷
Jean-Pascal Marc, Corporate Product Innovation Director, **Virbac** 🇫🇷
Eduardo O. Pontes, Associate Director Research Alliances Europe, External Innovation, **Zoetis** 🇮🇹

Start-up Slams

Sponsored by: **MERCK**

The Start-up Slams showcase **young promising companies** seeking to raise a seed or a Series A financing round.

Merck is awarding a special prize to the best start-up working on a biopharmaceutical therapeutic: **The Merck Advance Biotech Grant Award**. This prize includes:

- €30,000 to be used towards Merck's Bioprocessing technologies, Process Development Consultation & Services
- 2 hours of consultation time with M ventures

TUESDAY, DECEMBER 12TH | 9.00 - 10.30 AM

Innov'Area

ONCOLOGY

ORAKL ONCOLOGY 🇫🇷 **STAND IA 13**

Cancer | Techbio | Drug discovery and development

NASASBIOTECH 🇩🇪

Glioblastoma | Medical Device | Treatment

CASINVENT PHARMA 🇫🇷 **STAND IA 2**

Targeted therapy & resistance | Pancreatic cancer Gemcitabine | AML Venetoclax resistance

GLIOCURE 🇫🇷 **STAND IA 5**

Anti-mitotic peptide | Taxane resistant tumors | TUBB3

REACT THERAPEUTICS 🇫🇷 **STAND B13-A14/1**

Oncology | Multi-Drug Resistance | New Chemical Entities

ONCOSEMA 🇫🇷

Cancer monitoring | Circulating Tumor Cells | Blood test for oncology

DRUG DISCOVERY

URANIA THERAPEUTICS 🇫🇷 **STAND IA 22**

Genetic disease | Cancer | Small molecule

Start-up Slams

TUESDAY, DECEMBER 12TH | 2.00 - 3.00 PM

Innov'Area

INFLAMMATION

SURVIVX 🇫🇷 STAND IA 20

Sepsis | Immunomodulation | Adjuvant

PHIALOGICS 🇫🇷 STAND IA 16

Autoimmune disease | Biologics | Immune tolerance

NUMA HEALTH 🇫🇷 STAND IA 11

Preventive medicine | Personalized medicine | Bio-analytics

PERIOTRAP PHARMACEUTICALS 🇩🇪 STAND IA 15

Microbiome | Small molecule | Healthcare

TUESDAY, DECEMBER 12TH | 3.15 - 4.30 PM

Innov'Area

CNS

AMYL THERAPEUTICS 🇫🇷

Neurodegenerative diseases | Amyloidosis | Multi-targets binding

INNOVADE THERAPEUTICS 🇩🇪 STAND IA 7

Depression | Rapid Acting Antidepressant | Synaptic Plasticity

AGENT 🇫🇷

Alzheimer's Disease | Blood Test | Precision Medicine

MEDJEDUSE 🇫🇷 STAND B13-A14/4

Traumatic spinal cord injury | Tissue engineering biomaterial | Sensory-motor recovery

LACTABICO 🇩🇪 STAND IA 8

Peptides | Anxiety disorders | Metabolic disorders

Start-up Slams

WEDNESDAY, DECEMBER 13TH | 9.00 - 10.00 AM

Innov'Area

DRUG DISCOVERY

STH BIOTECH 🇫🇷 STAND IA 19

Bioproduction | Therapeutic cannabis | Metabolic engineering

REFOXY PHARMACEUTICALS 🇩🇪 STAND IA 17

Idiopathic Pulmonary Fibrosis | Ageing-diseases | FOXO3

ORIA BIOSCIENCE 🇫🇷 STAND IA 14

New intracellular targets | Organelles | High Throughput Screening

GENERARE 🇫🇷

Synthetic biology | Bioinformatics | Natural products

DIAGNOSTIC

MARX BIOTECHNOLOGY 🇩🇪

Health Care | Life Sciences | Diagnostics

WEDNESDAY, DECEMBER 13TH | 10.30 AM - 12.15 PM

Innov'Area

CARDIOVASCULAR & METABOLIC DISEASES

EXADEX-INNOV 🇫🇷 STAND B13-A14/2

Chronic metabolic diseases | Obesity | Cell therapy

TECHNOLOGY PLATFORMS

SEABELIFE BIOTECH 🇫🇷 STAND IA 18

First in class small molecule | Cell death inhibitor | Platform Technology

EVERSYN 🇩🇪 STAND IA 4

Biobetters & Biosimilars | Glycoengineering | Oligosaccharides

MT-ACT 🇫🇷 STAND B13-A14/3

NCEs | First in class | Cardiovascular

EPHYRA 🇫🇷 STAND IA 3

Sponge RNA | miRNA | Snowflake RNA (sfRNA)

Start-up Slams

WEDNESDAY, DECEMBER 13TH | 10.30 AM - 12.15 PM

Innov'Area

DRUG DELIVERY

NANOREVIV STAND IA 10

Drug Delivery Platform | Antibiotics | Bacterial resistances

APILLET STAND IA 1

Enteric encapsulation/coating | Nutraceuticals & pharmaceutical | Natural materials

THERALIA STAND IA 21

Drug delivery | Personalized medicine | Targeted antibiotics

WEDNESDAY, DECEMBER 13TH | 2.00 - 3.15 PM

Innov'Area

IMMUNOLOGY

BYORNA

RNA | Vaccine | Cancer

LOVALTECH

Nasal vaccines | Universal protein vaccine | Mucosal immunity

IMMUNEWATCH STAND IA 6

Immunology | T cells | AI

ONCO-IMMUNOLOGY

MODIBLAST PHARMA STAND IA 9

Leukemia | Immunomodulation | Dendritic Cell

ONCOBONE VENTURES STAND IA 12

Bone metastasis | Immunotherapy | Preclinical testing

Collaborative and licensing opportunity presentations

Co-organised by: **LEAP-BIO**  Funded by the European Union

The Collaborative and Licensing Opportunity Presentations showcase early-stage technologies from TTOs, universities, research institutes and companies.

TUESDAY, DECEMBER 12TH | 9.00 - 10.30 AM

Marseilleveyre room

INFECTIOUS DISEASES

NANOREVIV - STAPH-EX STAND IA 10

Lipid nano-capsules Platform | Antibiotics | Bacterial Resistance

AATEC MEDICAL - AAT

Inflammation | Respiratory | Inhalation

LILLE UNIVERSITY/ INSERM - CANDIDIASIS DIAGNOSIS

Candidiasis | Diagnosis | Monoclonal antibody

BIOASTER - COLICIN/IMMUNITY TECHNOLOGY

Multiplexing | Immunoassay | Diagnostic

G.ST ANTIVIRALS - 2-DEOXYGLUCOSE TREATMENT

Respiratory viral infections | 2-deoxyglucose | Spray and nebulizer

TUESDAY, DECEMBER 12TH | 5.00 - 6.15 PM

Marseilleveyre room

CELL & GENE THERAPY

FONDAZIONE TELETHON – 3D CELL CULTURE

3D cell culture | Gene Therapy | Nichioids

FONDAZIONE TELETHON – CASWITCH

Gene circuit | Biosensor | Inducible gene expressio (no leakiness)

FONDAZIONE TELETHON – IL-1RA GENE THERAPY

Gene Therapy | IL-1RA | Systemic Autoinflammatory Diseases

FONDAZIONE TELETHON – TOLEROGENIC DC TECHNOLOGIES

Tolerogenic Dendritic Cells | Autoimmune diseases | Cell Therapy

Collaborative and licensing opportunity presentations

TUESDAY, DECEMBER 12TH | 5.00 - 6.15 PM

Marseilleveyre room

CNS

CILCARE - AUDITORY MEASUREMENTS 🇫🇷 STAND E7-D10/7

Auditory | Biomarker | CNS

KVANTIFY - DRUG DISCOVERY TOOL 🇩🇪

Drug discovery | CNS | Small molecule

UNIVERSITY OF ANTWERP - INEUROVIR 🇧🇪

Viral infection | Neurodegenerative | High throughput screening

IOCB TECH 🇫🇷

Neurosteroids | Neuropathic pain | Epilepsy

WEDNESDAY, DECEMBER 13TH | 9.00 - 10.00 AM

Marseilleveyre room

ONCOLOGY

ERASMUS MC – CHROMSTRETCH 🇳🇱

DNA replication | Replication stress | Cancer

MINOS BIOSCIENCES - SINGLE-CELL ANALYSIS 🇫🇷

Oncology / Immuno-oncology | Single-cell functional analysis | Multi-omic analysis

SAN RAFFAELE UNIVERSITY AND RESEARCH HOSPITAL – CAR/TCR T CELL THERAPY 🇮🇹

CAR | Adoptive cell therapy | Cancer

UNIVERSITY OF GRENOBLE ALPES (UGA) – TERG 🇫🇷

Glioma | Antisense oligonucleotide | Sensitization

AKRIBION GENOMICS – G-DASE E 🇩🇪

Programmable anti-cancer drugs | RNA biomarkers | Head & neck cancer

Animal Health Presentations

Co-organised by:  **SIMV**
SARLAWAT INNOVATION MEDICINE BY DIAGNOSTIC VETERINAIRE

within  **SIMV**
R&D DATING FOR
ANIMAL HEALTH
AND INNOVATION

The Animal Health Presentations focus on innovations in relation to **animal well-being and health**.

TUESDAY, DECEMBER 12TH | 5.00 - 6.00 PM

Innov'Area

VETBIOLIX 🇫🇷

Cathepsin-K Inhibitor | Adenosin-A3 Agonist | 5-HT4 Agonist

MI:RNA 🇩🇪

Blood microRNA | Artificial Intelligence | Early disease diagnosis

VIRCO 🇫🇷

Antiviral | Corrol | Poxvirus / Herpes virus 

MYOMU 🇫🇷

Sarcopenia | Natural compound | NCE 

LUCKY 🇫🇷

Probiotic | Anti-proliferative | Pets 



 **Boehringer
Ingelheim**

**Working together
to solve the biggest
challenges in animal health**

Together with our global family of innovation partners, we're working hard to accelerate the discovery and development of the next generation of breakthroughs in animal health.

CardioMetabolic Diseases | Central Nervous System Diseases
Immunology & Inflammation | Infectious Diseases | Oncology | Oral Health
Pain & Osteoarthritis | Parasitology Technologies | Digital Science

Find out more:



Life forward

CONFERENCE PROGRAMME

Steered by an international committee, the BioFIT conference programme is shaped to correspond to the interests of every player in the sector and to meet the expectations of its stakeholders, whose sharp minds operate in the fast-paced Life Sciences sector. The 2023 programme is rooted in four custom-made tracks, addressing the right funding sources for **early-stage innovation**, best practices in **academia-industry R&D collaborations**, winning ways to **nurture early-stage assets** and **animal health highlights**.

TRACK 1

Best practices in R&D collaborations

Fostering academia-industry partnerships is key to driving innovation in Life Sciences. Which sectors are prone to fuel collaborations? What are the elements to forgather to merge the scientific, academic, advocacy and industry spheres? How are the advances in specific fields influencing academia-pharma partnerships?

TRACK 2

Nurturing and licensing early-stage assets

Early-stage assets evolve in an ecosystem where TTOs, scientists and entrepreneurs are closely connected. Understanding the mechanisms and difficulties in nurturing and licensing assets is key to properly influencing the valuation of these assets at an early stage. How can we transform science into business more frequently and efficiently?

TRACK 3

From pre-seed to Series A: Accessing early-stage investment

This track aims to understand the mechanisms enforcing investors' presence in early stages of development. Are we witnessing surges of investment in specific therapeutic areas? Who are the new players involved in investing in the biotech sector and what are their pre-requisites?

TRACK 4

Animal Health Highlights

This track features the latest innovation challenges in animal health R&D and intends to provide a clear understanding of the bridges that can be built between human and animal health. International experts from veterinary research and industry will discuss the latest initiatives to improve and accelerate the development of new diagnostics, vaccines and pharmaceuticals for animal diseases and beyond.

PLENARY SESSION

Lille room

Day 1 - Tuesday, December 12th | 11.00 am -12.30 pm

Biopharma industry has been facing uncertainties in 2023: What is the impact for early-stage partnering strategies?

In a global landscape marked by geopolitical complexities including inflation, conflicts, energy price fluctuations, and financial strains, investment opportunities and innovation dynamics have been challenged. As the industry navigates through a changing landscape, this session will explore how these uncertainties are shaping early-stage investment trends and consequently, strategies to forge successful partnerships.

What are the main current issues and opportunities in terms of financing and partnering in the EU biotech ecosystem compared to the US? Has the availability of capital really been affected at the seed and Series A stages? Are there any emerging trends or innovative approaches in early-stage collaborations that have emerged as a response? What are the impacts on the negotiation and terms of early-stage partnerships? How are biotech start-ups and pharma companies making the most of the current reality? What is the outlook for life sciences dealmaking in 2024?



Gilles Toulemonde
CEO
Inpart



Daniel Marshall
Director, oncology BD&L
MSD



Jan-Philipp Kruse
Senior Director BD&L & Open
Innovation – Head of Co.Lab
Berlin Incubator
Bayer



Robert de Jonge
VP Head of Corporate
Development
Mestag Therapeutics



Antoine Khallouf
Director - Healthcare Group
Rothschild & Co



Vanessa Carle
Associate
Forbion

TRACK 1

Best practices in R&D collaborations

Lille room

Day 1 - Tuesday, December 12th | 5.00 - 6.15 pm

Exploring collaborative practices between biotech start-ups and academia

What are the different models and approaches to collaboration that have proven successful in fostering partnerships between biotech start-ups and academia? Do biotech start-ups open multiple academic partnerships at early-stage? What about the relationship between a biotech spin-off and the university it stems from? How have collaborative practices between biotech start-ups and academia evolved over time, and what factors have driven these changes? What can be learnt from real-world examples and success stories of biotech start-ups/academia partnerships?



Jürgen Walkenhorst
Managing Director
Life Science Nord




Jean-Paul Fèvre
President
Temis Therapeutics



Timothé Cynober
Business Development Lead
WhiteLab Genomics



Jérémie Langlet
Business Development
Office Manager
Luxembourg Institute
of Health



Pascale Jordan
Partnership Head
Institut Pasteur

Day 2 - Wednesday, December 13th | 10.30 - 11.30 am Lille room

What are pharma companies' expectations for pre-competitive research?

Precompetitive collaboration provides a means to rapidly develop new capabilities and research outcomes. This session aims to provide valuable insights into the needs and aspirations of pharma companies when it comes to pre-competitive partnerships and how they align with other stakeholders. What are the current challenges and knowledge gaps they aim to address through collaborative efforts? What are the alternatives to large consortia? Are there new ways of financing pre-competitive research? What are pharma companies' rationale and benefits at this stage? What are the specific areas of research and priority topics of interest? What are the considerations around IP and data sharing? What are the key factors for successful outcomes in pre-competitive research collaborations?



Matthieu Flourakis
Team Lead Business
Innovation & Senior
Project Manager
Akkodis



Jürgen Bauer
Deputy Managing Director
EMBLEM
Technology Transfer



Joachim Vogt
Director, Search and
Evaluation International
Abbvie



Iraidia Soria-Espinosa
Senior Innovation and
Business Manager
UK Dementia
Research Institute



Anette Sommer
Senior Director, Emerging
Science & Innovation (ES&I)
- Lead Oncology Europe
Pfizer

Day 2 - Wednesday, December 13th | 3.30 - 4.30 pm Lille room

Best practices in managing early-stage academia-industry collaborations

Early-stage collaborations between academia and industry are essential for driving innovation in the biotech industry but can come with inherent risk and potential legal, financial, or scientific challenges specific to each party. How to align industry and academia's goals to make sure each party gets the most out of the collaboration? What are the common risks associated with early-stage academia-industry collaborations for both parties and how can they be identified and assessed from outset? What are the best practices in mitigating these risks and ensuring successful outcomes? How to manage intellectual property and confidentiality? How to measure the success of a collaboration?



Gerald Law
Chief Executive
Innovation DB



Julie Edwards
Director, Alliance
Management
Boehringer Ingelheim



Fadwa Benkessou
Alliances Manager
Karolinska Institutet



Nadine S. Sommerfeld
Business Development
Manager
Lead Discovery Center



Vassilis Georgiadis
Director of Industry Partnerships
King's College London



Siau Bai
Early Innovation
Partnering Director
Johnson & Johnson
Innovation

TRACK 2

Nurturing and licensing early-stage assets

Lille room

Day 1 - Tuesday, December 12th | 9.00 - 10.30 am

**Adding value to early-stage innovation through partnering:
What are the working models and how to valorise the partnerships?**

Valuing early-stage biotech innovations can be challenging due to the inherent risks and uncertainties associated. Yet, strategic partnerships can enhance the asset's valuation by providing access to resources, expertise, and potential market opportunities. How can partnerships be effectively structured to optimise value creation and provide a platform for long-term success? Are there partnership patterns and models which have proven to be effective? What are the contrasting strategies between platform-based innovations and single assets? How are future partners and investors evaluating collaborations in their due diligence?

Moderator



Claudia Andretta
Founder, Strategic Science
& Business Advisor
Sichem Bio 🇫🇷



Chris de Jonghe
Valorization Director
Oncode Institute 🇧🇪



Isabelle Scarabin
Director Business Development
& Licensing (Cell & Gene
and Ophthalmology)
Bayer Pharmaceuticals 🇩🇪



Lydia Kalafateli
Venture Developer &
Lead Biotech
NLC Health 🇮🇹



Jean Garrec
Founder & CEO
Biophta 🇫🇷

Day 1 - Tuesday, December 12th | 3.15 - 4.30 pm Lille room

How are tech transfer offices selecting the projects to back?

What are the key factors considered by tech transfer departments when evaluating project proposals? How do tech transfer offices assess the scientific and technological merit of projects? What key elements exist for these department to back a project? What about intellectual property considerations and evaluation of the potential for patenting and licensing? How do tech transfer offices align their project selection with the strategic objectives of their institution? Do new development models, such as VCs sourcing directly from universities or the emergence of start-up studios, affect TTO decision making?

Moderator



Gerald Law
Chief Executive
Innovation DB 🇬🇧



Youness Ouahid Benkaddour
Business Development
Manager
CANAAAN Research &
Investment Transfer 🇩🇪



Eleanor Price
Investment analyst
Thuja Capital 🇩🇪



Emma O'Neill
Technology Transfer Case
Manager, Life Sciences
Trinity College Dublin 🇮🇪



Brahim Sennane
Transfer & Licensing
Manager
CNRS Innovation 🇫🇷

Day 2 - Wednesday, December 13th | 2.00 - 3.15 pm Lille room

From lab to start-up: Let's hear about successful spin-out journeys

This session will showcase the journeys of biotech spin-outs and offer insight on the strategies and lessons learned from their experiences. How to decide whether to licence a technology to an existing company or set up a spin-off company to develop it? What are the key steps and challenges involved in spinning out a company based on academic research? What are the critical factors that contribute to a successful spin-out journey from academia to a start-up? What can the research group, university of origin or TTO concretely bring to the equation?

Moderator



Markus Lang
Managing Director
Dr Lang Consulting 🇩🇪



Judit Anido
CEO
Nuage Therapeutics 🇪🇸



Eric Halioua
President & Chief
Executive Officer
PDC*line Pharma 🇪🇸



Tim van Acker
New Ventures Manager
VIB 🇧🇪



Robert Zaïne Mamoun
CEO
CILOA 🇫🇷

TRACK 3

From pre-seed to Series A: Accessing early-stage investment

Lille room

Day 1 - Tuesday, December 12th | 2.00 - 3.00 pm

**Exploring the pharma-VC relationship:
How do they build complementary investment strategies?**

Pharma and VC firms have a symbiotic relationship, with VCs providing crucial funding to start-ups, and pharmaceutical companies offering strategic partnerships and potential acquisition opportunities. How do they align their investment strategies to maximise mutual benefits? How do pharma and VC firms manage their differing risk appetites and investment timeframes? What approaches do pharma and VC firms take to due diligence and decision-making processes? What is the place for the corporate VCs in the relationship?

Moderator



Bart Wuurman
CEO
Apaxen 🇧🇪



Nuno Alves
Associate Director,
Innovation Management
Astellas Europe 🇵🇹



Maya Chkaiban
Associate
Jeito 🇫🇷



Florence Dal Degan
Senior Director,
External Innovation
Ipsen 🇫🇷



Tugrul Ozdemir
Associate, Seed Investments
Novo Holdings 🇩🇰

Day 2 - Wednesday, December 13th | 9.00 - 10.00 am Lille room

What's new in non-dilutive funding across Europe and how to prepare for it?

Non-dilutive funding can be a game-changer for biotech companies, providing vital resources without diluting equity. What are the main sources of non-dilutive funding across Europe? What are the latest changes in grant financing, eligibility criteria, application processes? Are there specific funding opportunities or programs that are gaining traction in Europe, and what sectors or areas do they target? What are the key considerations and best practices for preparing successful grant applications? In which situations should non-dilutive funding be preferred? How to evaluate the potential impact of non-dilutive funding on business strategies and future growth?

Moderator



Jeroen Schuermans
Grant consultant
Akkodis 🇧🇪



Tobias Vöpel
EIC LiveSen-MAP
project coordinator
Technical University of Munich
Co-CEO
Nutrisen 🇩🇪



Anna Badurska
European Programs Lead
Cap Digital 🇫🇷



Timothé Cynober
Business
Development Lead
WhiteLab Genomics 🇫🇷

Day 2 - Wednesday, December 13th | 11.45 am - 12.30 pm Lille room

From Seed to Series A: What will spark investors' interest in 2024?

As we approach the end of the year, it's time to take stock of the exciting landscape of pre-seed, seed, and Series A funding in Europe and beyond. With a constant stream of innovations driving the biotech industry, what are the investment opportunities to watch for in 2024? Which models, therapeutic areas or innovative technologies are currently capturing the spotlight? What are investors' expectations regarding project maturity? How can early-stage biotech companies position themselves to be highly attractive for investment? Could we see a rise in pre-seed and seed money for 2024?

Moderator



Alexander Sindair Wilson
Associate Director of
Investments
Sanofi Ventures 🇫🇷



Tim Haines
Executive Partner
Abingworth 🇬🇧



Anela Vukoja
COO
Apollo Health Ventures 🇩🇪



Juliette Lee
Associate
EQT Life Sciences
Dementia Fund 🇬🇧



Adrien Clavairoly
Senior Associate
AdBio Partners 🇫🇷

TRACK 4

Animal Health highlights

Marseilleveyre room

Day 1 - Tuesday, December 12th | 2.00 - 3.00 pm

Sourcing innovations from a more mature human health market to build assets and start-ups in animal health: How is this happening?

With the human health market being more mature and well-established, there is an opportunity to leverage these innovations to address unmet needs in the animal health sector. This session will focus on the possibilities that the translation between both spaces can offer.

What factors determine the translational potential of human health innovations to the animal health market? How to identify suitable assets and how to articulate the translation process? What are the key steps involved in adapting and validating human health innovations for animal health applications? What are the collaborative models and partnerships that facilitate the sourcing and translation of human health innovations for animal health? Who are the players scouting from human to animal health?



Sven Arnouts
Business Development
Manager
PROVAXS – Ghent University 🇧🇪



Nuno Prego Ramos
President & CEO
CellmAbs 🇵🇹



Oliver Boucher
Senior Director,
Business Development
Zoetis 🇫🇷



Hanjo Henneman
Co-Founder & CEO
VEROVACCINES 🇩🇪



Hervé Poulet
Senior Director, Strategic
Partnering (R&D)
Boehringer Ingelheim
Animal Health 🇫🇷

Day 1 - Tuesday, December 12th | 3.15 - 3.45 pm Marseilleveyre room

Innovation and One Health:

How can partnerships accelerate strategic innovation?

Sponsored by: **zoetis**

One Health describes an approach calling for the collaborative efforts of multiple disciplines working locally, nationally, and globally, to attain optimal health for people, animals and our environment. Part of our One Health strategy at Zoetis is to foster partnerships with colleagues, communities and the people who care for animals in a way that recognises the interplay between these three domains. Important interlocutors for Zoetis include participants in the food chain, regulators, environmental protection agencies, researchers and grant-giving bodies, and other relevant actors able to reach across the boundaries between the three spheres of perspective which define One Health. Strategic innovation in One Health means finding technological and scientific opportunities which straddle these divides and which bring new ways of enhancing animal health to pet owners and livestock producers.



Didier Cochet
Business Unit Director
Zoetis France 🇫🇷



Dieter Vancraeynest
External Innovation Lead
Zoetis 🇧🇪



HOSTED EVENT

R&D dating for Animal Health and Innovation



BioFIT 2023 hosts the 9th edition of the “R&D dating for Animal Health and Innovation” business convention, at the initiative of the French association for the Animal Healthcare industry (SIMV).

Today, public-private and private-private partnerships are thought to be the leverage that is needed for innovation. That is why the SIMV launched the “R&D dating for Animal Health and Innovation”, which strives to initiate highlevel exchanges between research departments of the veterinary medicine and diagnostics industry and public research, as well as with biotechnology companies (start-ups). By enabling face-to-face encounters, the event enhances the visibility of cutting-edge research in France and in Europe, encourage investments and lead to therapeutic innovation.

Conference session:

Day 1 - Tuesday, December 12th | 2.00 - 3.00 pm Marseilleveyre room

Sourcing innovations from a more mature human health market to build assets and start-ups in animal health: How is this happening?

Animal Health Presentations:

Day 1 - Tuesday, December 12th | 5.00 - 6.15 pm Innov'Area

The Animal Health Presentations allow **young companies, TTOs, universities, research institutes** and **companies** to showcase their innovative project in front of potential partners and investors in the Animal Health sector.

Organised by:  **SIMV**
SYNDICAT DE L'INDUSTRIE DU
MÉDICAMENT ET DIAGNOSTIC VÉTÉRIAIRES

HOSTED EVENT

LEAP-BIO AI-powered digital platform: novel IP Licensing intermediary services of early-stage assets in pharma and biotech's

Day 1 - Tuesday, December 12th | 9.00 - 10.30 am Marseilleveyre room

LEAP-BIO



The brand-new LEAP-BIO Digital Platform has just been launched in late October 2023. Developed by INOVA with the LEAP-BIO consortium, the platform combines AI-powered digital tool and face-to-face partnering events on BioFIT. This will enable to promote licensing opportunities of early stage-assets from biopharma SMEs, start-up companies and TTOs towards Pharma & well-funded Biotech, favorising matchmaking processes.

LEAP-BIO co-organised the Collaborative and Licensing Opportunities Presentations at BioFIT.

About LEAP-BIO:

LEAP-BIO is a project funded by the Single Market Programme and aims to address the lack of intermediary services towards IP licensing and exploitation in key-target European regions/countries, such as Portugal, Spain, France, Italy and Wallonian region (Belgium).

The aim of the consortium is to develop an early-stage focused IP licensing intermediary service for biopharma SMEs and start-up companies in the target regions to contribute to drive the growth of the small and medium biopharma companies in such regions towards a more competitive European biopharma industry at a global level.

One major achievement of the project is the set-up of a sustainable IP licensing intermediary service of early-stage assets. Such newly developed tool consists in an AI-powered digital platform for matchmaking IP licensing interests, in association with the partnering platform on BioFIT to schedule one-on-one partnering meeting.

Partners:



EXHIBITOR LIST & FLOOR PLAN



AFSSI PAVILION

AFSSI	E7-D10
ANYGENES	E7-D10/3
ATLANTIC BONE SCREEN	E7-D10/9
AUDIT & RISKSOLUTIONS	E7-D10/6
BIOELPIDA	E7-D10/2
CILCARE	E7-D10/7
DRUGABILIUS	E7-D10/4
EVOLV CONSULTING - G.A.C. GROUP	E7-D10/5
COMPANY	E7-D10/1
MARSHALL BIORESOURCES	E7-D10/8
PORSOLIT	E7-D10/10
SYNCRYSOME	E7-D10/10
ALHENA CONSULT	D13
ANAPATH SERVICES GMBH	E4
ARTIALIS S.A.	G12
ASEPTIC TECHNOLOGIES	D5
ATLANPOLE BIOTHERAPIES	C11

BELGIUM-WALLONIA TRADE AGENCY

AGENCE WALLONNE À L'EXPORTATION ET	G3-F4
AUX INVESTISSEMENTS ÉTRANGERS	G3-F4/3
BRUSSELS SOUTH CHARLEROI BIOPARK	G3-F4/2
CMD-COAT SA	G3-F4/4
OP2LYSIS	G3-F4/5
ROMBIO	G3-F4/1
SECOVA TECHNOLOGIES	G3-F4/1

BICRO BIOCENTRE, LTD.	C1
BIOMAPAS	C9
CARBONEN AMCS	C13
CARNOT FRANCE FUTUR ELEVAGE	D9
CER GROUPE	B14
CHARLES RIVER LABORATORIES	B6
CHERRY BIOTECH	D1

CNRS

CNRS	B13-A14/5
EXADEX-INNOV	B13-A14/2
MEDJEDUSE	B13-A14/4
MT-ACT	B13-A14/3
REACT THERAPEUTICS	B13-A14/1

COLLABORATIVE DRUG DISCOVERY	A12
(CDD VAULT)	C16
DATAMARKIN	G10
DEEPIAB	C16
DELTA 2000 SRL	B16

DIVERSA TECHNOLOGIES S.L.	C12
EFOR GROUP	F5
ETHYPHARM	C14

HEALTHTECH IN SOUTH OF FRANCE

CANCEROPÔLE SUD	C7-A8/5
CILQA	C7-A8/3
CNCP	C7-A8/6
DOCCITY	C7-A8/11
EUROBIOMED	C7-A8/12
GAMMAOMICS	C7-A8/7
IODA CONSULTING	C7-A8/1
IPSO MEDIC	C7-A8/8
METROPOL AIX-MARSEILLE-PROVENCE	C7-A8/2
PHYLOGENE	C7-A8/4
PROVENCE PROMOTION	C7-A8/2
SOFTCELL THERAPEUTICS	C7-A8/9
VECT-HORUS	C7-A8/10

EUROFINS	F1
EUROFINS BIOPHARMA PRODUCT	F1
TESTING FRANCE	E12
EVOSENS	D17
FRANCE BIOTECH	D19
FUIREBIO	D6
GALENICA AB	E6
GROUPE ICARE	C3
HOLODIAG	B12
ICROM SRL	B10
IKAWERKE GMBH & CO. KG	G7
INNOSEER	C2
INTRAVACC B.V.	B20
KEDGE BS	F11

LILLE NORTHERN FRANCE BIOCLUSTER

CLUBSTER NHL	G1-F2
EURASANTÉ	G1-F2
INSTITUT CARNOT STAR	G1-F2/1
LEAP-BIO	G1-F2

MABION S.A.	F7
MEDITOX S.R.O.	C6
MICRONIT	G2
MICROSYNTH	C15
NEXTPHARMA	B2
NOVA BIOMEDICAL	B4
NOVALIX	F8
OZ BIOSCIENCES	E3
PARAS BIOPHARMA (BIOLOGICS CDMO)	C5

PCI PHARMA SERVICES	F8
---------------------	----

PIEDMONT LIFE SCIENCE INNOVATION CLUSTER-ITALY

APTOSOL	C17-B18/2
BIOPMED	C17-B18/1
CRESCENDOCARE	C17-B18/3
GEM FORLAB SRL	C17-B18/4

PORTON PHARMA SOLUTIONS LTD	C4
RÉSEAU SATT	F9-E10
ROOWIN S.A.	E2
SELVITA	D3
SIMV	C10
SOCIETY FOR LABORATORY	B11
AUTOMATION AND SCREENING (SIAS)	C19
SPARTNERS BY SERVIER & BIOLABS	B9
STERLING PHARMA SOLUTIONS	G8
SYNGENE INTERNATIONAL LTD	A10
TENSHI KAIZEN	E3
TRINITY COLLEGE DUBLIN	E5-D8
UNITHER PHARMACEUTICALS	B3-A4
X'PROCHEM	C8
ZOETIS	C8

INNOV'AREA

APILLET	IA 1
CASINVENT PHARMA	IA 2
EPHYRA	IA 3
EVERSYN	IA 4
GLIOCLURE	IA 5
IMMUNEWATCH	IA 6
INNOVADE THERAPEUTICS	IA 7
LACTABICO GMBH	IA 8
MODIBLAST PHARMA	IA 9
NANOREVIV	IA 10
NUMA HEALTH	IA 11
ONCOCONE VENTURES	IA 12
ORAKL ONCOLOGY	IA 13
ORIA BIOSCIENCE	IA 14
PERIOTRAP PHARMACEUTICALS	IA 15
PHALOGICS	IA 16
REFOXY PHARMACEUTICALS	IA 17
SEABELIFE BIOTECH	IA 18
STH BIOTECH	IA 19
SURVIVIX	IA 20
THERALIX	IA 21
URANIA THERAPEUTICS	IA 22

EXHIBITORS

AFSSI - STAND E7-D10

www.afssi.fr

The AFSSI, the French Association of Service and Innovation Companies for the Life Sciences has the desire to unite French companies of services and technological innovation in the strategic field of Life Sciences.

These innovative companies evolve in the pre-clinical phases, but also clinical, constitute the force of our sector; dynamic and highly qualified actors, constituting a diversified fabric of scientific providers essential to the development of industries in the Life Science.

AGENCE WALLONNE A L'EXPORTATION ET INVESTISSEMENTS ÉTRANGERS (AWEX)

STAND G3-F4 www.awex.be

The Wallonia Export & Investment Agency (AWEX) is the institution in charge of the development and management of Wallonia's domestic and international economic relations. Through a personalized, innovative, and sustainable approach, AWEX supports Walloon companies - regardless of their size, sector, or target market - in every step of their international endeavors. This includes exports, technological partnerships, and development abroad.

ALHENA CONSULT - STAND D13

www.alhena-consult.com

Alhena consult is a regulatory affairs consulting company providing advice on drug development and regulatory strategy while also offering project management services for Start-up in Europe. Our mission is to guide you in the translational activities from research to development, in light of the regulatory pre-requisites. We help you to achieve your development goals from your lead candidate to your first in human study.

ANAPATH SERVICES GMBH - STAND E4

www.anapath.ch

AnaPath Services (APS) based in Switzerland and AnaPath Research (APR) based in Spain are reputable CROs for Pharma, Biotech, (Agro) Chemical & MD companies. APR provides general toxicological studies, PK/PD, reproductive & developmental toxicology, veterinary products testing, bioanalytical services. APS is specialized in toxicologic pathology, histotechnology, necropsy, endocrine disruptor evaluation IHC, TCR, TEM, SEM, fetal & molecular pathology, material science.

ANYGENES - STAND E7-D10/3

www.anygenes.com

AnyGenes® is a R&D biotechnology, totally owned by its founders. Based on more than 15 years of experience, AnyGenes has three main activities: i) produces, manufactures and markets innovative and focused panel assays of signaling pathways, epigenetic (methylation analysis), microbiome and biomarkers profiling for translational medicine, ii) services for drug development by using our proprietary molecular platform, iii) development of multi-biomarkers clinical tests.

APTSOL - STAND C17-B18/2

www.aptisol.it

APTSol offers equipment and services in the field of technological processes for obtaining solid particles and powders. The company manage three main technologies: spray drying, spray congealing and ionic gelation. It provides high value-added services for the development of new formulations, process optimization and scale-up testing, as well as innovative equipment for activities and small productions.

ARTIALIS S.A. - STAND G12

www.artialis.com

Artialis is a Belgian biotechnology company offering Preclinical, Clinical, and Biotesting services. Our mission is to accelerate the development of ATMP, drugs, medical devices, and food supplements by being your partner of choice from the development to the commercialization of your product. We are specialized in Musculoskeletal, inflammatory, gastrointestinal, nutrition, and age-related disorders.

ASEPTIC TECHNOLOGIES - STAND D5

www.aseptictech.com

Aseptic Technologies manufactures fill & finish equipment and devices for advanced pharmaceutical manufacturing. Our core expertise lays in the innovation of aseptic filling processes for biopharmaceutical products, including cell and gene therapy products. As a member of SKAN Group, we leverage technological excellence of SKAN in the isolator design, providing integrated solutions for fill & finish projects, globally. We also offer customized ready-to-use cleanrooms assemblies.

ATLANPOLE BIOTHERAPIES - STAND C11

www.atlanpolebiotherapies.com

Atlanpole Biotherapies is involved in the medicine of tomorrow, with innovative areas of focus for the development of new therapies and the discovery of unexplored methodologies for human treatments. The projects of network, both academic and industrial, show the excellence of our expertise in personalized medicine. It is a European Center Of Excellence in 4 domains:

- Biotechnology & Pharma
- MedTech
- Digital Health
- Disease prevention (One Health)

ATLANTIC BONE SCREEN - STAND E7-D10/9

www.atlantic-bone-screen.com

Atlantic Bone Screen is a French CRO providing non-GLP preclinical services. We have a strong expertise in the field of osteoarticular indications / bone and joint diseases / biomaterials and in inflammation & oncology. We have developed in vitro tests, in vivo animal models and other platforms such as imaging, histology and histopathology. We support you to identify and characterize the therapeutic potential of your drug candidates, nutraceuticals and biomaterials.

AUDIT & RISKSOLUTIONS

STAND E7-D10/6

www.arsolutions.fr

Insurance broker which specialized in Life Sciences.

BICRO BIOCENTRE, LTD. - STAND C1

www.biocentre.hr

BIOCentre provides laboratories and offices, conducts technical and business training and consultancy for start-ups and established companies active in the biotech, pharma, food and agrotech fields. BIOCentre connects companies, universities and scientific institutes. Central Laboratory's units: Microbiology, Cell Biology, Downstream processing, Proteomics and Bioanalytical Chemistry are specialized to design the process optimization from biomass production up to a final biological product.

EXHIBITORS

BIOELPIDA - STAND E7-D10/2

www.bio-elpida.com

Established in 2009, BioElpida, a CDMO based in Lyon France, has continuously expanded its expertise and know-how in the development and GMP manufacturing of preclinical and clinical batches for start-ups and biotech companies engaged in innovative therapies. Our team of experts address biotherapies projects from late discovery to clinical phase 3 by offering flexible and tailor-made approaches in compliance with the regulatory framework. Our services also include cell banking and liquid aseptic fill & finish.

BIOMAPAS - STAND C9

www.biomapas.com

Biomapas is a premier CRO delivering flexible solutions globally throughout development as a seamless extension of your team. We can enhance your Drug Development, accelerate your path to Market Authorization, and ensure compliance with local and global Post-Marketing requirements through a complete service scope in Clinical Research, Regulatory Affairs, Pharmacovigilance, and Medical Information.

BIOPMED - STAND C17-B18/1

www.bioindustrypark.eu

bioPmed is the Piedmont innovation cluster dedicated to life science and health care. bioPmed since 2009 works to stimulate innovative activity by promoting collaboration, sharing of facilities and knowledge exchange. It combines over 90 companies, research centers, universities, foundations and service providers active in the fields of human health and life sciences, to promote the interaction between research and industry, stimulating innovation and accompanying internationalization processes.

BRUSSELS SOUTH CHARLEROI BIOPARK STAND G3-F4/3

www.biopark.be

Brussels South Charleroi BioPark is a campus that brings together a hundred players and 3,300 people involved in the research, development and production of new therapies, medical devices and diagnostic methods. We host subsidiaries of large international companies, SMEs from different countries, Belgian companies that are world leaders and three university research institutes from ULB and UMONS. This provides a rich environment in which to collaborate and grow businesses.

CANCEROPÔLE SUD - STAND C7-A8/5

www.canceropole-paca.com

The main objective of the Canceropole Sud is to gather and serve the academic, scientific, medical, and industrial community of Provence-Alpes-Côte d'Azur region working in the fight against cancer. Its aim is to accelerate cancer research in terms of benefits and improvement of outcomes for patients.

CARBOGEN AMCIS - STAND C13

www.carbogen-amcis.com

CARBOGEN AMCIS provides drug development and commercialisation services to the pharmaceutical and biopharmaceutical industries, at all stages of drug development. Our capabilities span from contract chemical process research and development to the supply of Active Pharmaceutical Ingredients (APIs) - as well as drug products for preclinical studies, clinical trials and commercial use. Besides being a service provider we also offer high quality Cholesterol and Vitamin D analog products.

CARNOT FRANCE FUTUR ELEVAGE - STAND D9

www.francefuturelevage.com

Carnot France Futur Elevage is a French public research network, certified by the French ministry of research, that provides R&D competences to livestock farming sector businesses, including animal health, genetic selection, animal nutrition, socio-economic changes in the livestock industry, and livestock farming practices. The main objective of Carnot France Futur Elevage is to develop public-private partnership in order to support innovations for tomorrow's sustainable breeding.

CER GROUPE - STAND B14

www.cergroupe.be

CER Groupe is an ISO/GLP-certified Belgian CRO (CIR certified) supporting human and veterinary health innovation through integrated and flexible bioproduction, non-clinical and analytical services meeting biotech, medtech, pharma, feed and food industries requirements. Our >200 collaborators are committed to offer best-in-class support to our partners, from discovery, hit to lead development and up to toxicity assessment, at the relevant quality standards (ISO9001, ISO17025 and GLP).

CHARLES RIVER LABORATORIES - STAND B6

www.criver.com

For over 70 years, Charles River has provided essential products and services to help pharmaceutical and biotechnology companies, government agencies, and academic institutions around the globe, helping to accelerate their research and drug development efforts. With over 90 sites globally, we're ready to tackle your product's most unique challenges. Our focus on timeliness and accuracy in every stage of drug development means you can count on us to deliver reliable results, every step of the way.

CHERRY BIOTECH - STAND D1

www.cherrybiotech.com

Cherry Biotech, a biomedical tech (Organ on Chip) firm, develops instruments for drug discovery and personalized medicine. We aim to replace animal testing by cultivating human tissue (Organoids) in vitro for drug evaluation. CubiX platform recreates immunocompetent human vascularized organ models and tumor microenvironments. This platform can uniquely transform a 2D multi-well plate into a 3D cell culture (Organ on Well), creating human 3D models mirroring physiology and pathophysiology.

CILCARE - STAND E7-D10/7

www.cilcare.com

CILCARE is a biotech dedicated to harnessing auditory sciences to reshape the future of care via early diagnosis and targeted treatment. We believe hearing acts as a valuable indicator of our health and must be monitored and preserved accordingly. As awareness of the link between hearing and chronic health conditions grows, auditory sciences are paving the way for the early detection of chronic neurocognitive, inflammatory, and age-related diseases.

CILOA - STAND C7-A8/3

www.ciloa.fr

Ciloa, a French preclinical biotechnology company and spin-off from CNRS and University of Montpellier, is a pioneer in the field of exosomes bioengineered in vivo with membrane and/or cytosolic proteins to develop innovative preventive and therapeutic solutions. Ciloa provides unique expertise and tools to develop high-potential exosomes as a technology platform. Leading candidates (T2D, vaccines) at the regulatory-enabling stage are open for licensing, and more offers will be announced soon.

EXHIBITORS

CLUBSTER NHL - STAND G1-F2

www.clubster-nhl.com

Clubster NHL – Nutrition, Health, Longevity – is a French competitiveness cluster federating 360 members in the Nutrition, Biotechnology and Health sectors. We foster collaboration between academia, private companies (start-up, SMEs and large companies), clinicians and final users. Our aim is to help our members to design, develop and finance their innovative products and processes.

CMD-COAT SA - STAND G3-F4/2

www.cmd-coat.com

CMD-COAT, a spin-off of the University of Liege (ULiege, BE), specializes in cardiovascular health research and bioactive coatings for medical devices. Founded in 2021 through collaboration between ULiege research centers and the Cardiology Department of the University Hospital of Liège, CMD-COAT developed the revolutionary COATI-X® coating technology allows for the simultaneous prevention of device-related thrombosis and infections, marking a significant advancement in medical device safety.

CNCPI - STAND C7-A8/6

www.cncpi.fr

The CNCPI, or Compagnie Nationale des Conseils en Propriété Industrielle, is a legal entity instituted by law and codified in the French Intellectual Property Code.

The CNCPI represents French Patent & Trademark Attorneys whose core business is to guide companies in the protection, defence, and promotion of their intellectual property rights (e.g trademarks, patents, designs, software, databases, new technology rights, etc.).

CNRS - STAND B13-A14/5

www.cnrs.fr

The CNRS is a key player in innovation, both in France and worldwide. Finding applications for research results ensures that scientific advances benefit society, which is one of the missions entrusted by the French government to the CNRS.

COLLABORATIVE DRUG DISCOVERY (CDD VAULT) - STAND A12

www.collaborativedrug.com

Collaborative Drug Discovery (CDD) provides an intuitive software suite extensively used by creative biologists and chemists working in academic, biotechnology and pharmaceutical settings. Their flagship product, CDD Vault, enables researchers to intuitively organize and analyze both biological and chemical data, and to collaborate with partners through a straightforward web interface.

CRESCENDOCARE - STAND C17-B18/3

www.crescendocare.it

CrescendoCare offers unparalleled bioanalytical consultancy, targeted analysis, and expert development of diagnostic methods and kits through IVDR-compliant instruments. With a focus on precision and innovation, the company specializes in targeted UPLC-MS/MS analysis for several biological samples, including mitochondria and PBMCs. Its extensive catalog covers a wide range of analytes, with specific applications in CardioRenal, Metabolic Inborn, Neuroscience, OncoHematology, and TDM.

DATAMARKIN - STAND C16

www.datamarkin.com

Empower life-science research with Datamarkin, where creating personalized AI models is as simple as a few clicks. Our no-code platform transforms unique imagery into highly accurate, custom AI models, elevating analysis to new heights. Without AI expertise, train models specific to your needs, ensuring precision and tailored insights. Datamarkin makes advanced image analysis accessible, fostering innovation and discovery in every project.

DEEPLAB - STAND G10

www.deeplab.ai

DeepLab, an innovative SME, has recently established itself in life sciences, applying its extensive research & advanced AI capabilities to areas like drug discovery and precision medicine. Our key products include drug screening, lead optimization, target identification through interpretable models, cancer subtype classification, generative AI for synthetic bio data and wellness capable brain computer interfaces. We seek partners who aim to employ ML for drug discovery and (pre-)clinical cases.

DELTA 2000 SRL - STAND B16

www.delta-2000.com

DELTA 2000 srl is your local and worldwide RELIABLE partner. In design, production and installation of cleanrooms for environments with controlled contamination.

Founded from the fusion of two important companies, working in developing and manufacturing of cleanrooms. Today DELTA 2000 boasts an experience over 20 years in the pharmaceutical medical chemical food cosmetic electronic and architectural fields.

Innovation, high-quality products technology and development are keywords in DELTA 2000.

DIVERSA TECHNOLOGIES S.L - STAND C12

www.diversatechnologies.com

DIVERSA, a biotech company, specializes in drug delivery using patented lipid nanoemulsions. We focus on meeting your molecule's unmet needs, offering efficient formulations for drugs and biomolecules, including RNAs. Our technology, also applicable in dermocosmetics and nutraceuticals, supports collaborations towards clinical trials. We provide reagents for easy formulation and mechanistic studies with fluorescent tracking. Our goal is to improve patient care with innovative, nanoemulsion-based therapeutics.

DOCCITY - STAND C7-A8/11

www.doccity.fr

DocCity, a real estate operator, is dedicated to create innovative environments for healthcare. Over three years, 120 million euros were invested in securing 25,000 square meters of healthcare-dedicated space in France. In late 2024, a «Totem» site in Marseille's 9th arrondissement will offer fully-equipped biomedical research labs, bio-production facilities, and biotherapy spaces. The real estate offering includes shared services and technical resources, fostering an innovative ecosystem with synergies in biotherapies. DocCity actively engages in biotechnology events in France, partnering with Eurobiomed to support biotech companies.

DRUGABILIS - STAND E7-D10/4

www.drugabilis.com

Drugabilis supports early R&D projects by fast and rationally developing early formulations for in vivo studies (efficacy, PK, Tox) in any species, optimizing the crystal form of new drug candidates and characterizing the physicochemical profiles of research compounds.

With an experience of about 20 years and 250+ clients, Drugabilis contributes to a faster selection of robust «drugs candidates» that will be able to fast undergo regulatory preclinical development phases to reach clinical trials.

EXHIBITORS

EFOR GROUP - STAND F5

www.efor-group.com

Founded in 2013, the Efor Group has positioned itself in 10 years as the leading European player in Life Sciences consulting.

With more than 2,000 employees in 19 offices in France, Belgium, Switzerland, and the USA, we leverage our expertise and methods to assist our clients in securing the market approval and maintenance of healthcare products in a constantly evolving technical and regulatory environment.

ETHYPHARM - STAND C14

www.ethypharm.com

Ethypharm is a pharmaceutical company focused on CNS and Hospital injectables through direct sales, distribution and licenses.

Ethypharm is also offering CDMO services from formulation, clinical trials, till validation.

Sterile forms (Ampoule, PFS, Vials, Lyo) and conventional (complex solid dosage forms and orals), using conventional API, High potent and Controlled drugs with a great expertise in taste masking, pellets and orodispersible technologies.

EURASANTÉ - STAND G1-F2

www.eurasante.com

Eurasanté is a development agency dedicated to tech transfer and business development in life sciences sector in Northern France region. Our experienced project managers help researchers, start-ups and companies with their development projects. To do so, Eurasante provides many services such as real estate, fundraising, recruitment and business development. It also promotes the Eurasante Bio-business Park, which already hosts 10 hospitals, 4 universities, 8 specialised schools and more than 200 companies. It benefits from an exceptional location at the heart of Europe.

EUROBIOMED - STAND C7-A8/12

www.eurobiomed.org

EUROBIOMED is the catalyst of the health sector in Southern France. EUROBIOMED leads territorial initiatives, provides resources and offers solutions for businesses and research organizations. EUROBIOMED helps them to innovate, finance, develop and achieve their strategic and business objectives to ultimately improve life through innovations in health. EUROBIOMED tops European rankings in all stages of innovation. Together, the + 420 EUROBIOMED members are a driving force in regional development (with 390 projects, representing +1,5 billion Euros).

EUROFINS - STAND F1

www.eurofins.com/biopharma-services/cdmo/services/adme-cdmo-optimized

Eurofins ADME BIOANALYSES services: Small & Large Molecule Bioanalyses, Biomarkers & Metabolites, Method Development & Validation, ADME, PK/PD, Discovery, Pre-Clinical & Clinical, Topical Product Development.

Eurofins CDMO services: Preformulation, Formulation Development, DP Manufacturing, Clinical Trial Supply and Logistics, CMC/RA.

Eurofins OPTIMED services: Protocol Development & Study Design, Regulatory Analysis / Submission, Site and Trial Monitoring & Management, Bioanalysis, Biometry.

EUROFINS BIOPHARMA PRODUCT TESTING FRANCE - STAND E12

www.eurofins.fr/biopharma-product-testing

The Eurofins BioPharma Product Testing France laboratory network is a CRO that provides the pharmaceutical, biotechnology and medical device industries with analytical services, in accordance with regulations (EMA, FDA, ISO, etc.) and current GMP, GLP and Cofrac standards, for the development and marketing of human and veterinary (bio)drugs and medical devices.

EVOLY CONSULTING - G.A.C. GROUP COMPANY - STAND E7-D10/5

www.group-gac.com

EVOLY Consulting, a G.A.C. Group company, backed by Bpifrance, supports innovative businesses in leveraging funding mechanisms aligned with their R&D projects, covering everything from R&D tax incentives to national and European grant initiatives.

EVOSENS - STAND D17

www.evosens.fr

EVOSENS is a specialist in the integration of custom photonic systems, with two complementary activities:

- engineering, focused on the design and update of photonic systems. We have skills in optics, electronics, mechanics and IT. We develop solutions using softwares ZEMAX, SOLIDWORKS, ALTIUM.

- manufacturing, dedicated to prototyping and manufacturing customized solutions. We have high-end facilities: 60 m² cleanroom, optical laboratory, equipment such as wavefront analyzers, spectrometers...

EXADEX-INNOV - STAND B13-A14/2

www.exadex-innov.com

ExAdEx-Innov develops an innovative and upscalable biotherapy for the treatment of obesity-associated chronic metabolic diseases in total therapeutic failure, such as NASH, as well as Type-2 diabetes and complex obesity forms not responding to treatments. The patented ExAdEx core technology also allows to derisk drug development through a unique R&D ex vivo platform of human adipose tissue mimicking pathological contexts to generate clinically-relevant data at preclinical stage.

FRANCE BIOTECH - STAND D19

www.france-biotech.fr

France Biotech, founded in 1997, is an independent association that brings together the country's leading innovative health companies. As a leader in health innovation and a privileged intermediary with public authorities in France and Europe, France Biotech's mission is to support the development of this industry in France, by improving the tax, legal, regulatory and managerial environment in which these companies operate and by advocating for their recognition as a leading-edge industry.

FUJIREBIO - STAND D6

www.fujirebio.com

Fujirebio is an R&D-driven company constantly developing new technologies and unique biomarkers with high clinical value. Our group mission is to create new value in healthcare and thereby contribute to human health and the future of medical care.

Our main focus are the neurodegenerative diseases (CSF and plasma markers), infectious diseases and oncology.

GALENICA AB - STAND E6

www.galenica.se

Galenica is a Swedish pharmaceutical company with activities in drug delivery and pharmaceutical development. Galenica performs extensive development work including preformulation, analytical method development, formulation development and quality control on pharmaceutical products, including all common dosage forms. Galenica also supports in manufacturing of clinical trial material from Phase I to Phase III as well as small scale commercial production.

EXHIBITORS

GAMMAOMICS - STAND C7-A8/7

www.scenith.com

Welcome to GammaOmics, your partner in advanced personalized medicine. Discover SCENITH™, our groundbreaking single-cell technology for immuno-metabolic profiling. It offers unique insights into cellular metabolism, crucial for research in immunology, oncology, and metabolic studies. Our innovative SCENITH Flow cytometry product and Metabolomic Panel enable precise, single-cell analysis, revolutionizing metabolic research. Benefit from our research service and ImmunoProfiling Platform.

GEM FORLAB SRL - STAND C17-B18/4

www.gemforlab.com

GEM FORLAB provides analytical services for life science industry (Pharma and Medtech companies, start up and CRO); thanks to a multidisciplinary approach, we deliver fit-for-purpose solutions, in compliance with GLP & GCP principles, when required. Our mission is to give Customers support throughout the R&D processes (discovery, Preclinical and Clinical studies (phase I-III), allowing them to boost licensing opportunities and fulfill regulatory requirements.

GROUPE ICARE - STAND C3

www.groupeicare.com

ICARE, SPECIALIST IN HEALTHCARE PRODUCT SAFETY CONTROL.

For over 28 years, Groupe ICARE services have been bringing clients the assurance that their marketed device or product meets regulatory and normative requirements. Our teams guide you and share their expertise in all stages of the life cycle of health products thanks to the 5 Icare skills centers, from concept to control of production (Biocompatibility & toxicology, laboratory testing, validation & qualification, formation & consulting).

HOLODIAG - STAND B12

www.holodiag.com

CRO dedicated to solid state and crystallization processes of small molecules since 2006.

Our services are:

- Analytical characterizations: we are equipped with XRPD, DSC, TGA, DVS, FTIR, Laser PSD, IDR,... All analyses are available on toxic samples down to 50 ng/m³
- Solid state screenings: Polymorphs, salts, co-crystals. Properties investigations on stability, solubility, dissolution
- Crystallization processes: Development from scratch, optimization of existing process, trouble shooting.

ICROM SRL - STAND B10

www.icrom.com

ICROM is an API CDMO specialized in development and GMP manufacturing of Active Ingredients; with over 50 years of experience, ICROM is the partner of choice for pharmaceutical outsourcing, able to provide a wide range of tailored services, custom development and custom manufacturing of NCEs, generic APIs, 'high-tech' and difficult to make molecules for complex formulations.

IKA WERKE GMBH & CO. KG - STAND G7

www.ika.com

IKA laboratory technology offers a wide range of innovative equipment for numerous applications in research and development. IKA has gained a leading position in the world market with its innovative bioreactors, magnetic stirrers, mixers, overhead stirrers, shakers, homogenizers, mills, centrifuges, pipettes, and specially developed software for laboratory and analysis applications, as well as temperature control products such as circulators, baths and incubators.

INNOSER - STAND C2

www.innoserlaboratories.com

As an innovative and dynamic CRO, InnoSer supports the preclinical pipeline from its facilities in Belgium and the Netherlands. Our in-depth expertise allows us to provide customized and streamlined early drug development options with well-characterized and near-patient research models. Our services are designed with personalized tailoring in mind, supported by innovative technical capabilities, and are executed in close collaboration with our partners.

INSTITUT CARNOT STAR - STAND G1-F2/1

www.carnotstar.univ-amu.fr

Carnot STAR is composed of 9 research units in the field of Sport, Health and Well-being. We offer to industries a complete portfolio of scientific expertise and know-how to support them on multidisciplinary R&D and innovation projects.

INTRAVACC B.V. - STAND B20

www.intravacc.nl

Intravacc is an established independent CDMO with years of experience in developing and optimizing vaccines for infectious diseases and therapeutic vaccines, we have transferred our technology worldwide for vaccines against polio, measles, diphtheria, Hib, and influenza. Around 30% of childhood disease vaccines are based on our technology and knowhow. We offer a wide range of expertise for vaccine development, from concept to Phase I/II clinical studies, for customers around the world.

IODA CONSULTING - STAND C7-A8/1

www.iodaconsulting.fr

IODA Consulting is a consulting company with a recognized expertise for innovative companies for more than 20 years. We are beside companies at all stages of maturity, especially in healthcare.

We offer 3 kinds of high value services:

- Accountancy.
- Management of R&D tax credits.
- Funding research.

More, our fifty people team integrates besides finance profiles engineers, PhDs, senior strategy consultants in innovation funding to define and drive their development plan at their side.

IPSOMEDIC - STAND C7-A8/8

www.ipsomedic.com

IPSOMEDIC and IPSOMEL develop innovative continuous flow processes.

Our aim is to provide sustainable solutions for the manufacture of pharmaceutical ingredients in Europe at a competitive cost. Based on our patents, a first manufacturing unit is under construction in France, and will provide access to a drug that is regularly out of stock. Our Aubagne site brings together experts in chem & biotech processes, PAT and data science. It includes R&D laboratories. Pilot units are being built.

KEDGE BS - STAND F11

kedge.edu

KEDGE supports your Talent Management.

Every year, KEDGE welcomes more than 6,000 professionals looking to develop their career, train and strengthen specific skills. The School supports people with their development goals and companies with their ambitions to expand both in France and abroad, whether they are seeking a complete transformation or new areas of expertise. Let's talk about our tailored solutions dedicated for international groups and SMEs during the BioFIT 2023 in Marseille.

EXHIBITORS

LEAP-BIO - STAND G1-F2

European project LEAP-BIO aims at bridging the gap between different European regions in licensing and partnering associated with early-stage assets, driving the growth of the small and medium biopharma companies and contributing to a more competitive European biopharma industry at a global level. It has developed an early-stage focused IP licensing digital platform for biopharma SMEs and start-up companies that combines AI-powered digital tool and face-to-face partnering events on BioFIT.

MABION S.A. - STAND F7

www.mabion.eu

Mabion is a fully integrated CDMO offering a wide range of services related to the development and production of protein-based biotherapeutics, including monoclonal antibodies and vaccine antigens. With 16 years' of experience, Mabion offers end-to-end solutions covering all stages of biologic drug development, from early clone selection and small-scale production, through process scale-up, large-scale manufacturing and quality control to sterile fill&finish, bioanalytics and regulatory support.

MARSHALL BIORESOURCES

STAND E7-D10/1

www.marshallbio.com

Our mission is to be the premier source of animal models and related services for the preclinical research and development of human medicines, vaccines, medical devices, and other therapies, as well as for the clinical research and development of companion animal pharmaceuticals. We hold ourselves to the highest standards of health and quality, and AAALAC accreditation serves to enhance our top commitment to animal care and welfare.

MEDITOX S.R.O. - STAND C6

www.meditox.eu

MediTox is a GLP-certified CRO having experience in variety of compounds and therapeutic areas, with an experts and associates teams capable to conduct a number of experiments in full compliance with GLP standards and with another international guidelines (EMA/ICH, VICH, OECD, US FDA, ISO10993), providing core range of nonclinical studies supporting phases I - III of clinical trials and/or registration of human & veterinary drugs, medical device, food/feed additives.

MEDJEDUSE - STAND B13-A14/4

www.medjeduse.com

Traumatic spinal cord injury is a huge unmet need for which there is no therapeutic solution. Medjeduse develops a proprietary biomaterial (Chitosan form) as a neurosurgical medical implant to heal spinal cord injuries that cause locomotor and sensory loss. A proof of concept has been achieved in rat preclinical models. A larger animal study in pigs is ongoing before executing a first-in-human clinical trial.

MÉTROPOLE AIX-MARSEILLE-PROVENCE

STAND C7-A8/3

www.ampmetropole.fr

With 92 municipalities and 1.8 million inhabitants, the Aix-Marseille-Provence metropolis is the economic capital of the South region, the Euro-Mediterranean center of exchanges and the 2nd French metropolis in demographic terms. With 92,000 jobs, 20,000 students, 47 research laboratories, a world competitiveness cluster, 600 innovative companies and four axes of excellence (microbiology, infectious diseases and genetic diseases; neurosciences; medical instrumentation and immunology) the health sector supported by the Metropole is positioned as an international sector.

MICRONIT - STAND G2

www.micronit.com

Micronit is a trusted leader in high-quality microfluidic solutions. Their specialized team empowers clients to bring innovative products to market in life science and healthcare with cutting-edge technology and personalized support. Founded in 1999, the company has extensive experience in developing and manufacturing high-quality products for customers worldwide. Micronit's products are used in a variety of applications, including life science and healthcare.

MICROSYNTH - STAND C15

www.microsynth.com

Microsynth (founded in 1989) is a leading European company in nucleic acid synthesis & analysis. The main activities are divided into following three business areas:

- DNA/RNA Synthesis
- DNA/RNA Analysis and Sequencing
- Contract Research/Outsourcing

MT-ACT - STAND B13-A14/3

www.mt-act.com

MT-act is a preclinical stage CNRS spin-off biotech that devised MT-discover®, a unique discovery platform that generates small molecules to safely restore microtubule cytoskeleton function in age-related diseases. We successfully employed MT-discover® in the space of cardiology and now expect it to fuel additional programs in the CNS. At MT-act, we ambition to bring innovative drug products to the clinic as treatment for several chronic diseases to improve patient's life.

NEXTPHARMA - STAND B2

www.nextpharma.com

NextPharma is a EU CDMO with 10 sites located in Europe. NextPharma provides services from early pharmaceutical development, clinical supplies, scale-up and process validation through to commercial manufacturing for a large range of dosage forms like tablets, capsules, granules, pellets, gels, creams, liquid solutions & suspensions, ophthalmics, incl. specific niche expertise such as high potent, hormone, controlled drugs, lipid based and modified release formulations (Soft and hard capsules).

NOVA BIOMEDICAL - STAND B4

www.novabiomedical.com

Founded in 1976 and headquartered in Waltham, MA, Nova Biomedical is a world leader in the development and manufacture of whole blood analyzers, point-of-care and critical care analyzers, and cell culture monitoring analyzers for the biotechnology market.

Nova manufactures BioProfile® automated cell culture analyzers for rapid analysis of metabolites, pH, osmolarity, gases and cell density/viability for a wide range of cell culture applications.

NOVALIX - STAND F3

www.novalix.com

NovAliX is a fully integrated drug discovery CRO supporting therapeutic programs from target identification to the delivery of preclinical candidates. NovAliX enables successful discovery programs through an award-winning team of medicinal chemistry and pharmacology scientists, and a variety of screening and characterization technologies, including an outstanding DNA-encoded library platform and a comprehensive portfolio of biophysical techniques, including an in-house cryo-EM facility.

EXHIBITORS

OP2LYSIS - STAND G3-F4/4

www.op2lysis.com

Op2Lysis is a French-Belgian biotech company developing innovative treatments for patients with cerebrovascular thrombotic diseases, including orphan drug indications. Looking to raise €5M EUR, to complete their €27M EUR Series A round. The proceeds will be to (i) complete a combined Phase 1/2 clinical study of their lead asset O2L-001 in patients with hemorrhagic stroke and (ii) develop pipeline, based on their unique NANOp2Lysis® platform, for other indications including ischemic stroke.

OZ BIOSCIENCES - STAND E8

www.ozbiosciences.com

OZ Biosciences creates & markets specialized life science research reagents. The company expertise's are in drug delivery systems, transfection reagents, transduction tools, mRNA production, magnetic -, lipid- & polymer-based nanoparticles. OZB conceives cutting-edge technologies such as transfection reagents for bio-production (protein & virus), viral enhancer for cell therapy engineering, mRNA & LNP custom services for nucleic acid therapy and vaccines.

PARAS BIOPHARMA (BIOLOGICS CDMO) FINLAND - STAND C5

www.parasbiopharma.com

Paras Biopharma (Biologics CDMO) Finland offers Biologics CDMO Services, Biologics/Biosimilar Technology Development & Scale-up, & co-development & licensing partnership opportunities of high-value Biologics. Our unique technologies (Diabrid®, Biomultifold®, Noblecleav® & Cytotfold StructQuant®) facilitates high productivity & quality of biologics. With expertise in critical areas inc. development of complex proteins (early-stage - large scale) and of enzymes for medicinal & bioprocess purposes.

PCI PHARMA SERVICES - STAND F8

www.pci.com

PCI provides a global service with localized focus, delivering over 200 protocols a year in over 100 countries, utilizing best-in-class technologies combined with our experienced and dedicated teams. Providing a seamless service, PCI supports the global supply of IMPs with pharmaceutical development, clinical drug product manufacturing, packaging, labeling, storage and distribution.

PHYLOGENE - STAND C7-A8/4

www.phylogene.com

PHYLOGENE is a R&D and testing company which developed a platform using functional omics and bioinformatics for untargeted effects discovery to deliver mechanisms of action or biomarkers. Among these, metaproteomics is now very efficient to compare for example stool samples, quantify the over- and underexpression of proteins before data processing. Also, our company characterize raw materials in terms of their identification/quantification of large molecules, proteins and nucleic acids.

PORSOLT - STAND E7-D10/8

www.porsolt.com

We are an internationally recognized and long established global preclinical CRO (GLP accredited), providing preclinical services encompassing drug discovery, screening, and safety testing using standardized and innovative techniques. Our expertise spans various therapeutic domains like Pain, CNS, CV, Inflammation, Oncology, Metabolism and Dermatology. We provide in vitro, in vivo, ex vivo, histology, and bioanalytical services to assist pharmaceutical, biotech, academic, and non-profit sectors.

PORTON PHARMA SOLUTIONS LTD

STAND C4

www.portonpharma.com

With over 5,000 customer-centric employees, operations and commercial offices across the US, EU and China, Porton Pharma Solutions provides global pharmaceutical companies with innovative, reliable and end-to-end process R&D and manufacturing services across small molecule APIs, dosage forms and biologics.

PROVENCE PROMOTION - STAND C7-A8/2

www.investinprovence.com

For 25 years, Provence Promotion has been the main contact for companies looking to INVEST IN PROVENCE. Our multicultural team of 23 experts facilitates the establishment of projects in key sectors such as health, biotechnologies and medical technologies, opening the doors of local ecosystems to French and foreign investors. As an economic development agency, we provide free, confidential guidance. Get in touch to realise your investment ambitions in Provence!

REACT THERAPEUTICS - STAND B13-A14/1

www.react-therapeutics.com

ReACT Therapeutics developed 5th-gen potent and selective inhibitors to target Breast Cancer Resistance Protein, a key treatment failure cause. Our globally protected lead compound extends the duration of drug effects in existing and new cancer drugs. We could impact across >40 known cancer drugs and >14 cancer indications. Our lead compound combined with irinotecan, a gold standard chemotherapy, has not only doubled irinotecan's efficacy but also increased mouse survival by a factor of 5.

RÉSEAU SATT - STAND F9-E10

www.satt.fr

The SATT Network brings together 13 Technology Transfer Offices (TTOs) in France. SATTs are committed to foster economic development by providing companies with high-potential technological solutions stemming from French public research to improve their competitiveness. Local, trusted players, we are connected on a daily basis to over 150,000 researchers, and offer privileged access to innovations from public laboratories. We detect, evaluate, protect inventions and bring innovation to the market by entrusting them to an existing company or a future startup. We finance their technological development through an exclusive investment fund. With over 750 startups created, SATTs are the first-class local players in the French Government's DeepTech Plan, operated by Bpifrance. With our nationwide network, we are strategic partners for companies seeking growth through innovation.

ROMBIO - STAND G3-F4/5

www.rombio.be

Rombio uses artificial intelligence to generate operational schedules, according to the company's KPIs, resources and constraints, optimised while taking uncertainty into account. Managers can monitor and adapt operations, anticipating future resource requirements, simulating resource investments, ...

ROOWIN S.A. - STAND E2

www.roowin.com

Roowin S.A. is a French Contract Research Organization with 26 years of experience. Our core business is fine chemistry with high value, supporting our customers from early drug discovery process development (GLP quantities) through medium-scale GMP production (up to 30 kg) with strong CMC capabilities. Roowin extended its footprint in the U.S.A opening Roowin Inc. the wholly owned subsidiary of Roowin S.A. in San Diego (CA, U.S.A) in 2022.

EXHIBITORS

SECOYA TECHNOLOGIES - STAND G3-F4/1

www.secoya-tech.com

Secoya Technologies is an innovative solution-driven company with over 10 years of in-house expertise. Today we empower a faster time-to-market for your novel medicine thanks to the seamless scale up enabled by our equipment. Secoya Technologies has developed 3 innovative technologies, based on the principles of microfluidics, in the field of crystallization, emulsification and pervaporation. For each one of those, we provide ranges of robust intensified reactors affording enhanced productivity.

SELVITA - STAND D3

www.selvita.com

Selvita is a preclinical CRO providing multidisciplinary support in resolving the unique challenges of research within the areas of drug discovery and drug development.

The company offers support at every stage of the early discovery phase up to the preclinical development. Selvita specializes in a variety of processes from in silico drug design and synthesis of a target-focused library, to complex preclinical in vitro and in vivo pharmacology, and structural biology.

SIMV - STAND C10

www.simv.org

The French association for animal health industry (SIMV) represents manufacturers and marketers (on the French market) of medicines and reagents for pets and for farm animals. In order to contribute to the competitiveness of its member companies, the SIMV defines its value creation through its trades:

- Federating ;
- Anticipating;
- Advising/training/informing;
- Being watchful;
- Representing the positions of its members.

SOCIETY FOR LABORATORY AUTOMATION AND SCREENING (SLAS)

STAND B11 www.slas.org

SLAS is a global professional society of academic, industry and government life sciences researchers coupled with developers and providers of laboratory automation technology. SLAS advances scientific innovation by providing education, collaboration and professional development that unites scientists across disciplines to transform research.

SLAS2024: Boston, 3-7 February - 6000 delegates, 350 exhibitors

SLAS Europe 2024: Barcelona 27-29 May - 1000 delegates, 125 exhibitors

SOFTCELL THERAPEUTICS - STAND C7-A8/9

www.softcell-therapeutics.com

SCT offers a disruptive and novel manufacturing process capable of increasing the production of innovative cell therapies, while boosting manufacturing yields and the quality of cultured cells. The improved performance of this link in the value chain is accompanied by a reduction in the associated production costs.

SPARTNERS BY SERVIER & BIOLABS

STAND C19

www.servier.com

Spartners by Servier & BioLabs is on a mission to empower life science innovation in Paris-Saclay by creating a unique place for life science startups to test, develop and grow game changing ideas. Spartners offers fully equipped laboratory and office spaces that are supported by an experienced, dedicated, technical team. Designed to build community, Spartners enables high-potential life science companies to work, collaborate and innovate in a setting perfectly suited to meet their needs.

STERLING PHARMA SOLUTIONS

STAND B9

www.sterlingpharmasolutions.com

Sterling Pharma Solutions is a global contract development and manufacturing organisation with 50+ years' experience in providing small molecule API development and manufacturing services to the pharmaceutical industry. Sterling specialises in handling challenging chemistries, and also offers Antibody Drug Conjugate development and manufacturing.

Sterling has six facilities across the UK, US and Ireland, employing 1,350+ people.

SYNCROSOME - STAND E7-D10/10

www.syncrosome.com

SYNCROSOME provides relevant disease models (in cardiology, CNS, gastroenterology, metabolic disorders and respiratory fields), cutting-edge techniques, specific biomarkers and comprehensive background of physiopathology to assist drug discovery companies in selecting their compounds.

SYNCROSOME has developed and validated so far more than 20 disease models, and our flexible and human sized organization can design and operate tailored in vivo experimental.

SYNGENE INTERNATIONAL LTD

STAND G8

www.syngeneintl.com

Syngene International Ltd. is an innovation focused global discovery, development and manufacturing organization providing integrated scientific services to the pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical industries around the world.

TENSHI KAIZEN - STAND A10

www.tenshi.co.in/insta-pill-rapid-dissolve-tabs

Tenshi Kaizen's InstaPill Freeze Dried Oral Dispersible tablet technology is the ideal platform for patient centric medicines for patients with Dysphagia or for medicines on the move / rescue treatments. We have a proven taste-masking toolkit and commercial products marketed by partners in USA, Canada, EU, UK and Australia. We are a CDMO with a very flexible business model and low cost of development. Come to booth A10 to try a placebo tablet.

TRINITY COLLEGE DUBLIN - STAND E3

www.tcd.ie

Trinity College Dublin, the University of Dublin has a proud tradition of performing world class research and translating this research excellence into solutions with global economic and social impact. Trinity is the top ranked university in Ireland. Using the QS methodology we are ranked 81st in the world and using the Times Higher Education World University Rankings methodology we are 146th in the world.

UNITHER PHARMACEUTICALS - STAND E5-D8

www.unither-pharma.com

Created in 1993, Unither Pharmaceuticals is a French CDMO dedicated to health products and specialized in sterile single doses and non-sterile liquids. It supplies the main global markets from a unique industrial network of 8 factories spread across 4 continents – North America, South America, Europe and Asia – and an R&D center of expertise mainly on the formulation of ophthalmic products. Unither pharmaceuticals has a turnover of 500 million euros and a workforce of 2,200 people.

EXHIBITORS

VECT-HORUS - STAND C7-A8/10

www.vect-horus.com

VECT-HORUS designs and develops vectors to facilitate the targeted delivery of drugs or imaging agents into the brain and other organs. By combining pharmaceutical agents to its vectors, VECT-HORUS enables their transport across the BBB, which significantly impedes brain delivery of most drugs. Proof of concept of the technology was demonstrated in animal models for different vectorized molecules, among them the endogenous neuropeptide neurotensin.

X'PROCHEM - STAND B3-A4

www.xprochem.com

Founded in 2012, X'PROCHEM is a CRO (Contract Research Organization) specialized in chemical protein synthesis.

We design and produce therapeutic proteins for our pharmaceutical and biotech partners. We manufacture complex and highly customized proteins up to 400 amino acids (40 kDa) by using an automated process.

ZOETIS - STAND C8

www.zoetis.com

As the world's leading animal health company, we are driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After 70 years innovating ways to predict, prevent, detect, and treat animal illness, we continue to stand by those raising and caring for animals worldwide – from livestock farmers to veterinarians and pet owners. A Fortune 500 company, we generated revenue of \$8.1 billion in 2022 with ~13,800 employees.



THEY SUPPORT US

PLATINUM SPONSORS



GOLD SPONSOR



SILVER SPONSORS



BRONZE SPONSORS



CONTRIBUTING SPONSORS



THEY SUPPORT US

MAIN SUPPORTERS



SUPPORTERS



OUR PARTNERS



MEDIA PARTNERS



SAVE THE DATE



Biofit

FOSTERING
INNOVATION
& TRANSFER

The leading European partnering event
for early-stage deals and investment
rounds in the Life Sciences field

**December
3rd & 4th, 2024
LILLE**



13TH EDITION

Organisers:



Institutional partners:



With the support of:



Sponsors:

